Introduction {#s1}
============

The metabolism of all cells must adapt to meet the energetic and biosynthetic needs of growth and homeostasis ([@bib40]; [@bib78]). For example, tissues composed of non-dividing, differentiated cells must strike a balance between catabolic pathways that provide energy for cellular homeostasis and anabolic pathways that repair the cell and generate cell-type-specific molecules ([@bib40]). In contrast, the metabolic requirements of cell growth and proliferation often require a shift toward anabolic pathways that favors the synthesis of macromolecules, such as proteins, lipids, nucleic acids, and complex carbohydrates ([@bib78]). Striking this delicate balance between degradative and biosynthetic processes requires the integration of extracellular and intracellular information by complex signaling networks.

The mechanisms by which cell proliferation and tissue growth rewire metabolism to enhance biosynthesis are diverse and complex ([@bib42]). These changes in metabolic flux involve pathways such as the pyrimidine and purine biosynthesis, one carbon metabolism, and the interplay between the citric acid cycle and amino acids pools. However, the pathway most commonly associated with enhanced biosynthesis is glycolysis, where in biological systems ranging from yeast to human T-cells, glycolytic flux is often elevated in the context of cell growth and proliferation ([@bib78]). This observation is particularly apparent in the fruit fly *Drosophila melanogaster*, where the onset of larval development is preceded by a metabolic switch that induces the coordinate upregulation of genes involved in glycolysis, the pentose phosphate pathway, and lactate dehydrogenase (LDH) ([@bib64]). The resulting metabolic program allows larvae to use dietary carbohydrates for both energy production and biomass accumulation. Moreover, studies of *Drosophila* larval muscles reveal that this metabolic transition is essential for muscle growth and development, suggesting that glycolysis serves a key role in controlling growth ([@bib66]). The mechanisms that control glycolysis specifically in larval muscle, however, remain relatively unexplored. As a result, *Drosophila* larval development provides an excellent model for understanding how glycolysis and biomass production are regulated in a rapidly growing tissue. Moreover, since larval muscle increases in size without cell divisions, larval muscle provides an unusual opportunity to understand how glycolytic metabolism promotes growth independent of cell division.

Of the known factors that promote muscle development, TRIM32 is an intriguing candidate for coordinating metabolism with cell growth. This protein is a member of the Tripartite motif (TRIM)-containing family of proteins defined by an N-terminal RING domain, one or two B-boxes, a coiled-coil domain, and a variable C-terminal region ([@bib69]; [@bib73]). In TRIM32, six [N]{.ul}cl-1, [H]{.ul}T2A, [L]{.ul}in-41 (NHL) repeats comprise the C-terminus and are proposed to mediate the diverse functions of TRIM32, including cell proliferation, neuronal differentiation, muscle physiology and regeneration, and tumorigenesis ([@bib34]; [@bib69]; [@bib73]). A single mutation in the B-box region of TRIM32 causes the multisystemic disorder Bardet-Biedl syndrome (BBS) ([@bib10]), while multiple mutations that cluster in the NHL domains result in the muscle disorders Limb-girdle muscular dystrophy type 2H (LGMD2H) and Sarcotubular Myopathy (STM) ([@bib7]; [@bib21]; [@bib33]; [@bib49]; [@bib50]; [@bib58]; [@bib59]).

A complete understanding of TRIM32 function is confounded by its ubiquitous expression and multitude of potential substrates for E3 ligase activity via the RING domain. Many known TRIM32 target substrates include proteins implicated in muscle physiology ([@bib4]; [@bib13]; [@bib12]; [@bib30]; [@bib41]; [@bib71]) or the prevention of satellite cell senescence ([@bib31]; [@bib46]; [@bib59]), consistent with a role for TRIM32 in LGMD2H. However, additional polyubiquitinated substrates, including p53, Abi2, Piasy, XIAP, and MYCN, are implicated in tumorigenesis ([@bib4]; [@bib28]; [@bib29]; [@bib39]; [@bib57]). Importantly, TRIM32 protein levels are upregulated in multiple tumor types, suggesting that TRIM32 is a key player in growth regulation ([@bib25]; [@bib27]; [@bib77]). There is precedence for NHL function in controlling cell proliferation as two other *Drosophila* NHL-containing proteins, Brat and Mei-P26, act as tumor suppressors in the larval brain and female germline, respectively ([@bib5]; [@bib19]).

Here, we provide a novel mechanism for TRIM32 in cell growth. Our data show that TRIM32 promotes glucose metabolism through the stabilization of glycolytic enzyme levels. This increased rate of TRIM32-mediated glycolytic flux generates precursors that are utilized for biomass production. Surprisingly, this mechanism operates in both non-dividing muscle cells as well as in proliferating larval brain cells, demonstrating a universal metabolic function for TRIM32 in growth control.

Results {#s2}
=======

TRIM32 binds to glycolytic enzymes {#s2-1}
----------------------------------

While NHL domain-containing proteins can interact with both RNAs and proteins ([@bib69]; [@bib73]), few bona fide TRIM32 binding partners have been identified. Causative mutations in human LGMD2H cluster in the NHL repeats ([Figure 1A](#fig1){ref-type="fig"}; [@bib7]; [@bib14]; [@bib21]; [@bib33]; [@bib49]; [@bib50]; [@bib58]), suggesting that this region may mediate protein-protein interactions important in disease prevention. We previously showed that mutations in *Drosophila* TRIM32 also show progressive larval muscle degeneration, despite modest sequence identity (\~42%) across the NHL domains ([@bib32]). To gain molecular-level insight into the functional conservation between the NHL regions in fly and mammalian TRIM32, we obtained a crystal structure of TRIM32_NHL at 2.6 Å resolution (Rwork/Rfree = 18.2/22.8%) ([Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}; [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). The structure was solved by molecular replacement, using the NHL-repeat region of the *Drosophila* Brat protein as a search model (PDB Code 1Q7F) ([@bib19]). This structure features a six-bladed β-propeller, where each NHL repeat is comprised of four antiparallel β-strands ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). We then used the TRIM32_NHL structure to construct a model for mouse TRIM32_NHL using SWISS-MODEL. Indeed, the superimposition of these two structures demonstrate that the NHL region of *Drosophila* TRIM32 is a faithful model to understand NHL function ([Figure 1B](#fig1){ref-type="fig"}).

![The NHL region of *Drosophila* TRIM32 is structurally conserved.\
(**A**) Schematic showing the RING, B-box, coiled-coil, and NHL domains in TRIM32. (**B**) Superimposed protein structures of the six NHL repeats in *Drosophila* (magenta) and *Mus musculus* (blue) TRIM32. Each NHL repeat consists of four antiparallel beta sheets that are arranged toroidally around a central axis. Mouse NHL has two additional loops (asterisks) not present in the fly protein. The positions and orientation of both R394/R1114 and D487/D1211 are identical between *Mus musculus* and *Drosophila *(orange). (**C**) The glycolytic pathway. Peptides corresponding to enzymes that co-purified with TRIM32_NHL are shown in blue.\
Figure 1---source data 1.X-ray diffraction data collection and refinement statistics.\
Figure 1---source data 2.Proteins identified via MS that co-purify with TRIM32-NHL Experiment \#1 (1418) Experiment \#2 (1426.1) Experiment \#3 (1426.2).](elife-52358-fig1){#fig1}

To identify TRIM32_NHL-interacting proteins, we performed in vivo pulldowns followed by mass spectrometry (MS) to uncover associated peptides. Briefly, the C-terminal region of *Drosophila* TRIM32 containing all six NHL domains (AA 1061--1353) was fused in-frame with an N-terminal Glutathione S-transferase (GST) tag. This GST_TRIM32_NHL protein was expressed, purified, and incubated with third instar larval (L3) lysates. These resulting protein complexes were subjected to MS to detect peptide fragments that co-purify with TRIM32_NHL. In addition to the recovery of our bait protein, we detected peptides corresponding to Tropomyosin (Tm) and Troponin T (TnT) ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}), which are both known polyubiquitinated substrates of mammalian TRIM32 ([@bib12]). Surprisingly, glycolytic enzymes were also enriched in the list of possible NHL-binding proteins ([Figure 1C](#fig1){ref-type="fig"}; [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}) and were further evaluated for physical interactions with TRIM32.

We utilized two independent methods to validate candidate protein interactions with TRIM32. First, an in vitro binding assay using purified proteins was developed with Tropomyosin 2 (Tm2) as a positive control. Indeed, incubation of TRIM32_NHL together with His-tagged Tm2 confirmed a physical interaction between these two proteins ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This assay was then used to test for physical interactions with candidate glycolytic enzymes. To this end, we expressed and purified His-tagged Aldolase (Ald) or His-tagged Phosphoglycerate mutase 78 (Pglym), both of which were low or absent in control pulldowns. Both Ald and Pglym were found to directly interact with the NHL domains of TRIM32 ([Figure 2A,B](#fig2){ref-type="fig"}). Note that no binding was detected between TRIM32_NHL and the His-tagged control protein SCIN, ruling out non-specific binding of the His tag. To extend these findings, we utilized immunoprecipitation experiments to test for in vivo interactions with full-length TRIM32. As expected, immunoprecipitation of TRIM32 successfully pulled-down Tm as an interacting protein at the predicted molecular weight of \~37 kD ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). We also confirmed that both Ald and Pglym co-immunoprecipitate with anti-TRIM32 antibody. Interestingly, the bands corresponding to these proteins migrated at a higher molecular weight than the expected size present in input lysates ([Figure 2C,D](#fig2){ref-type="fig"}; asterisk), suggestive of a post-translational modification. Two approaches were taken to confirm the specificity of the slower migrating bands that correspond to Ald or Pglym. First, we concentrated L3 lysates before SDS-PAGE analysis. After overexposure of the western blots, faint bands corresponding to the higher molecular weight forms of Ald or Pglym were present ([Figure 2C,D](#fig2){ref-type="fig"}; asterisk). We also immunoprecipitated TRIM32 from larval lysates and probed for Ald or Pglym using antibodies raised against the orthologous human proteins (ALD or PGAM1). While these antibodies did not cross react well in input lysates, there was an obvious band corresponding to the higher molecular weight forms of both Ald and Pglym after pulling down TRIM32 ([Figure 2---figure supplement 1D,E](#fig2s1){ref-type="fig"}). Collectively, these data demonstrate that Ald and Pglym interact with the NHL domain of TRIM32 and in vivo, a subpopulation of these post-translationally modified glycolytic enzymes can be found in a complex with TRIM32.

![*Drosophila* TRIM32 physically interacts with the glycolytic enzymes Ald and Pglym78.\
(**A,B**) In vitro binding assays. Untagged TRIM32_NHL was incubated with either the His-tagged SCIN control protein or the His-tagged candidate proteins Ald (**A**) or Pglym (**B**). After washing in 300 mM NaCl and 0.1% Triton, each of these protein complexes was separated by SDS-PAGE followed by Coomassie staining. Ald and Pglym proteins directly bind the NHL region of TRIM32, while no interaction with the His-SCIN control protein is observed. (**C,D**) Western blotting with antibodies against *Drosophila* Ald (dAld; **C**) or *Drosophila* Pglym (dPglym; **D**) detects higher molecular weight bands (asterisk) upon immunoprecipitation of *Drosophila* TRIM32, but not in control lanes. The observed molecular weights of Ald or Pglym in input larval lysates (\~30 µg) is predominant over a higher migrating form that can be visualized after overexposure of blots with concentrated lysate (\~300 µg). (**E,F**) Western blots showing that mutations in *tn* reduce Ald (**E**) or Pglym (**F**) protein levels \~ 50% quantitated relative to ATP5α in L3 larvae. N = 3. Mean +/- SD (\*, p\<0.05).](elife-52358-fig2){#fig2}

The majority of TRIM32 studies have focused on the biological impact of polyUb chain addition onto substrates ([@bib12]; [@bib30]; [@bib39]; [@bib41]; [@bib46]). This modification targets a protein for proteasomal degradation and usually increases protein substrate levels in the absence of its E3 counterpart. Indeed, the known mammalian substrate Tm binds to TRIM32_NHL ([@bib12]) and accordingly, *Drosophila* Tm was modestly increased in larvae mutant for *tn* ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Strikingly, this same loss of TRIM32 resulted in a \~ 50% decrease in the protein levels of Ald or Pglym78 ([Figure 2E,F](#fig2){ref-type="fig"}). This downregulation was not due to a decrease in TRIM32-mediated transcription as mRNA levels of *Ald* or *Pglym* were not altered in *tn-/-* ([Figure 2---figure supplement 1F,G](#fig2s1){ref-type="fig"}). Taken together, these data highlight a unique role for TRIM32 in the stabilization of glycolytic enzyme levels.

Loss of TRIM32 disrupts glycolytic metabolism in larval muscles {#s2-2}
---------------------------------------------------------------

To understand the biological implications for the physical interaction between TRIM32 and the glycolytic enzymes Ald and Pglym, we profiled 85 metabolites present in *WT* or *tn-/-* L3 larvae. Principal component analysis (PCA) revealed a distinct separation between *WT* and *tn-/-* experimental groups ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Examination of individual metabolites upon loss of TRIM32 showed a decrease in the terminal glycolytic products pyruvate and lactate as well as significant depletion of the glucose-derived metabolites glycerol-3-phosphate and 2-hydroxyglutarate ([Figure 3A,B](#fig3){ref-type="fig"}). These metabolic changes suggest that TRIM32 is required for sustaining the conversion of glucose to pyruvate and lactate in L3 larvae.

![Loss of TRIM32 decreases glycolytic flux and reduces muscle tissue size.\
(**A**) Volcano plot illustrating fold change (FC) (log base 2) compared with p-value (- log base 10) between *WT* and *tn-/-* L3 larvae. Vertical line represents FC \>1.5. Horizontal line depicts a significance level p\<0.05. Metabolites that are reduced in *tn-/-* larvae include indicators of glycolytic flux (green) and amino acids (blue). Metabolites in gray are significant, but exhibit a FC \<1.5. (**B**) Box and whisker plot of terminal glycolytic metabolites significantly reduced upon loss of TRIM32. N = 6. (**C--F**) Ventral longitudinal muscles 3 (VL3) and 4 (VL4) stained with phalloidin to visualize F-actin (green). (**C,D**) The stereotypical morphology of *WT* muscles is not altered as overall muscle size increases from the L2 (**C**) to the L3 (**D**) stage. (**E,F**) In addition to sarcomeric disorganization, the VL3 and VL4 muscles are noticeably smaller in *tn-/-* larvae during L2 (**E**) and L3 (**F**) development. Muscle attachment sites (MASs) are denoted by yellow lines. (**G**) Scatter plot depicting VL3 muscle diameter. The diameter of *WT* muscles increase from the L2 to the L3 stage. This cell size increase is abolished in *tn-/-.* N ≥ 8. (**H**) Bar graph shows that ECAR measurements are decreased in isolated *tn-/-* muscle carcasses compared to *WT*. N ≥ 4. (**I**) Analysis of the glycolytic rate in *WT* or *tn-/-* muscle tissue after subtraction of mitochondrial-produced acidification. This PER is diminished upon loss of TRIM32. N = 4. (**J**) NADH lifetime image comparison of *WT* and *tn-/-* muscles. Box and whisker plot shows *WT* muscles have significantly lower NADH lifetime, indicative of higher glycolytic flux, than *tn-/-*. N = 5. Mean +/- SD. (\*\*\*\*, p\<0.001; \*\*\*, p\<0.01; \*, p\<0.05; n.s., not significant). Scale bars: 25 µm (**C,E**), 50 µm (**D,F**).](elife-52358-fig3){#fig3}

The production of pyruvate at the end of glycolysis has two fates, either a reduction to lactate or oxidation to CO~2~ in the mitochondrion ([@bib47]; [@bib67]). To determine if reduced lactate levels in *tn-/-* results in increased respiration and therefore elevated ATP synthesis, we assessed these two outputs of overall energy metabolism in control or mutant whole larvae. Respirometry analysis revealed a modest increase in CO~2~ production upon loss of TRIM32 ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). However, ATP levels were significantly decreased in *tn-/-* larvae ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Given that different larval tissues may have altered metabolic profiles that influence outputs of whole body metabolism, we sought to assess glycolytic activity in individual tissues.

A unique aspect of *Drosophila* larval development is the 200-fold increase in body size from first instar (L1) larvae through the L3 stage. In order to support high levels of biomass accumulation, glycolytic metabolism is increased prior to larval growth ([@bib64]; [@bib66]). One larval tissue that requires high glycolytic activity is the somatic musculature, where *WT* body wall muscles undergo dramatic growth as development proceeds from second instar larvae (L2) ([Figure 3C,G](#fig3){ref-type="fig"}) to the L3 stage ([Figure 3D,G](#fig3){ref-type="fig"}). We, and others, previously reported a loss of structural integrity in TRIM32-deficient muscles ([@bib18]; [@bib32]) and assumed that the associated reduction in muscle size was a secondary consequence of progressive tissue degeneration. While multiple independent alleles of *tn* have been shown to produce smaller muscles ([@bib18]; [@bib32]), quantification of *tn-/-* confirmed a decrease in larval muscle diameter in both L2 ([Figure 3E,G](#fig3){ref-type="fig"}) and L3 individuals ([Figure 3F,G](#fig3){ref-type="fig"}). Thus, loss of TRIM32 compromises the glycolytic-driven growth of muscles during larval development.

As an initial assessment of glycolytic activity, we measured the extracellular acidification rate (ECAR) in *WT* or *tn-/-* muscle carcasses using the Agilent Seahorse XFe96 Analyzer. Since a major contributor to extracellular acidification is lactate excretion into medium during glycolysis ([@bib48]; [@bib67]), we anticipated, and indeed, observed a reduction in ECAR upon loss of TRIM32 ([Figure 3H](#fig3){ref-type="fig"}). While quantitative, end-point assays such as ECAR, only measure a population of muscles at a single time point. For real-time measurements of glycolytic flux, the Xe96 Analyzer was used to calculate the proton efflux rate (PER). This assay specifically provides a measurement of protons derived from glycolysis by correcting for both the production of protons derived from mitochondrial reactions and for the buffering capacity of the assay medium. Briefly, the assay measures ECAR of the system under three conditions: (1) without manipulation, (2) following addition of the electron transport chain inhibitors rotenone and antimycin A, and (3) after addition of the glycolytic inhibitor 2-deoxy-D-glucose (2-DG). The end result of the assay is a measurement of acidification rate largely due to glycolytic sources. Our analysis revealed that glycolytic metabolism produces fewer protons in *tn-/-* muscle carcasses as compared with *WT* controls ([Figure 3I](#fig3){ref-type="fig"}), thus supporting our hypothesis that TRIM32 is required to support glycolytic flux.

To independently validate that loss of TRIM32 results in decreased glycolytic flux, we directly measured NADH levels within muscle tissues using fluorescence lifetime imaging (FLIM), which exploits the fluorescent characteristic of this cofactor to visualize NADH levels in cellular microenvironments ([@bib43]; [@bib55]; [@bib62]; [@bib75]). Since the fluorescent lifetime of NADH (the time required for NADH to decay when exposed to 740 nm wavelength light) is longer when NADH is bound to mitochondrial enzymes than in the free state, this assay can distinguish intracellular NADH pools ([@bib6]; [@bib60]). This analysis revealed that *WT* muscles analyzed by FLIM showed a markedly shorter lifetime than *tn-/-* muscles ([Figure 3J](#fig3){ref-type="fig"}). Since free, unbound NADH is predominate in highly glycolytic cells, here we confirm a reduction in the glycolytic profile upon loss of TRIM32. These data, taken together, strongly support the hypothesis that TRIM32 maintains glycolytic flux in larval muscle tissue.

One consequence of analyzing *tn* mutant alleles is the possibility that the observed muscle defects result from loss of TRIM32 in other tissues. To rule out TRIM32-mediated systemic defects, we utilized tissue-specific RNAi approaches ([@bib8]). First, we reconfirmed that induction of three independent RNAi constructs targeting *tn mRNA* transcripts with the *mef2*-Gal4 muscle driver produced smaller muscles ([Figure 4A,B,D](#fig4){ref-type="fig"}; [@bib9]; [@bib18]; [@bib32]). Knockdown of TRIM32 in a single muscle (5053\> \>*tn RNAi*, asterisk) within each hemisegment was sufficient to reduce muscle cell size ([Figure 4C](#fig4){ref-type="fig"}). As a proxy to monitor glycolytic activity, we assayed L-lactate levels in muscle carcasses. Consistent with our metabolomics data, the relative concentration of lactate levels was decreased in *tn-/-* muscles ([Figure 4E](#fig4){ref-type="fig"}). Induction of *tn RNAi* in muscle tissue (*mef2 \>tn RNAi*) decreased lactate levels, while this same reduction did not occur upon TRIM32 knockdown in neurons (*elav \>tn RNAi*) ([Figure 4E](#fig4){ref-type="fig"}). Here, we conclude that TRIM32-mediated regulation of glycolysis in muscle tissue is cell autonomous.

![Muscle defects are cell autonomous and can be rescued upon stabilization of glycolytic enzyme levels.\
(**A--E**) Knockdown of TRIM32 in muscle tissue decreases muscle size and reduces lactate levels. (**A--C**) Phalloidin-labeled VL1-4 muscles in a representative hemisegment of the indicated genotypes. (**A**) *mef2\>+* control muscles appear *WT*. (**B,C**) RNAi knockdown of *tn* in all muscles with *mef2*-Gal4 (**B**) or only muscle VL1 using the *5053*-Gal4 driver (**C**) show a reduction in muscle size (asterisk). (**D**) Knockdown of *tn* mRNA transcripts with three independent UAS-*tn RNAi* constructs in muscle tissue under control of the *mef2* promoter (*mef2 \>tn RNAi*) show reduced VL3 muscle diameter compared to *mef2/+* VL3 muscles. N ≥ 10. (**E**) Bar graph reveals a cell autonomous role for TRIM32 in muscle tissue. L-lactate levels in muscle carcasses are decreased upon loss of TRIM32 in all tissues. Induction of *tn RNAi* in muscle, but not neuronal tissue, reduces the concentration of muscle-derived lactate. N \> 8. (**F--J**) Muscle-specific expression of TRIM32 (*tn-/-, mef \>TRIM32*) or ERR (*tn-/-, mef \>ERR*) in a *tn-/-* background attenuates the loss of muscle size, muscle contraction, and stabilizes glycolytic protein levels. (**F**) Scatter plot shows that the reduced VL3 muscle diameter upon loss of TRIM32 is restored upon expression of TRIM32 or ERR in muscle tissue. N ≥ 10. (**G,H**) The inability to contract body wall muscles in *tn-/-* causes elongated pupae. Muscle-specific expression of TRIM32 or ERR restores muscle contraction. (**G**) Representative pupal cases of the indicated genotypes. (**H**) Quantitation of pupal axial ratios represented by a box and whisker plot. N = 10. (**I,J**) Western blots showing the relative amounts of Ald or Pglym protein relative to the ATP5α loading control. Both Ald and Pglym protein levels are stabilized upon TRIM32 or ERR expression in muscle tissue compared to *tn-/-.* N = 3. Mean +/- SD (\*\*\*\*, p\<0.001; \*\*\*, p\<0.01; \*\*, p\<0.05; \*, p\<0.01; n.s., not significant).](elife-52358-fig4){#fig4}

Estrogen-related receptor (ERR) is a nuclear hormone receptor that acts as a transcriptional switch in embryogenesis to induce genes required for aerobic glycolysis during larval growth ([@bib64]). Therefore, we posited that genetic upregulation of carbohydrate metabolism genes via ERR may improve muscle growth and function. As a positive control, we expressed a cDNA encoding for TRIM32 in *tn-/-* muscle tissue (*tn-/-; mef \>TRIM32*) and found that the muscle diameter was restored to *WT* ([Figure 4F](#fig4){ref-type="fig"}). This result also confirmed the cell autonomy of TRIM32. Overexpression of ERR in *tn-/-* muscles not only improved muscle size ([Figure 4F](#fig4){ref-type="fig"}), but also corrected the functional deficit associated with the inability of *tn-/-* to contract body wall muscles during pupal morphogenesis ([Figure 4G,H](#fig4){ref-type="fig"}; [@bib18]; [@bib32]). Importantly, protein levels of Ald and Pglym were stabilized upon expression of ERR in *tn-/-* muscles ([Figure 4I,J](#fig4){ref-type="fig"}), indicating that restoration of glycolytic protein levels is sufficient to recover TRIM32-mediated growth defects.

TRIM32 maintains amino acid pools {#s2-3}
---------------------------------

Our metabolomics analysis revealed that loss of TRIM32 not only disrupts the production of glycolytic intermediates, but also induces a significant decrease in eleven of the twenty amino acids ([Figure 5A](#fig5){ref-type="fig"}). These changes in amino acid abundance are likely due to both decreased synthesis and increased catabolism ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), as we observed that *tn-/-* exhibited a\>1.5 decrease in not only serine and glycine levels which are normally synthesized from glucose, but also a reduction in the anaplerotic amino acids proline and aspartic acid. Moreover, loss of TRIM32 also induced a significant depletion of alanine, which is both synthesized from and catabolized into pyruvate. Overall, the metabolomic profile of *tn-/-* indicates that disruption of glucose catabolism results in depletion of larval amino acid pools, raising the possibility that decreased amino acid availability contributes to the *tn-/-* muscle defects. We tested this possibility by supplementing the diets of both mutant and control larvae with amino acid sources. As an initial approach, we first determined if the *tn-/-* larval phenotype exhibited enhanced sensitivity to nutrient deprivation. Indeed, when reared on starvation media, the muscle diameter of *tn* mutants was smaller than muscles of control larvae raised on the same media ([Figure 5B,C,F](#fig5){ref-type="fig"}). In contrast, mutant larvae fed a diet consisting of only yeast extract or supplemented with all 20 amino acids exhibited no decrease in muscle diameter ([Figure 5D,E,F](#fig5){ref-type="fig"}). We observed similar results in the context of L3 body mass and muscle contraction during the larval to pupal transition, whereby *tn-/-* raised on an agar-only diet exhibited dramatically more severe phenotypes compared with *WT* control larvae ([Figure 5G,H,I](#fig5){ref-type="fig"}). Supplementation of the larval diet with yeast extract or amino acids, however, suppressed both phenotypes in *tn-/-* ([Figure 5G,H,I](#fig5){ref-type="fig"}). These results suggest that *tn-/-* mutants are uniquely sensitive to dietary amino acids, consistent with the smaller amino acid pool size observed upon loss of TRIM32.

![Amino acid supplementation is sufficient to improve *tn-/-* muscle mass.\
(**A**) Box and whisker plots showing the relative abundance of individual amino acids in L3 larvae with a FC \>1.5 (left panel) or FC \<1.5 (right panel) that are significantly reduced upon loss of TRIM32. N = 6. (**B--E**) Maximum intensity projections of *WT* (**B**) or *tn-/-* (**C--E**) L3 muscles stained for F-actin. Upper panel depicts two complete hemisegments and lower panel focuses on the VL3 and VL4 muscles. MASs are denoted by yellow lines. (**B**) An example of thinner *WT* musculature reared on agar as a sole nutritional source. (**C**) Muscles in larvae deficient for TRIM32 are substantially thinner when raised on agar alone. (**D,E**) Suppression of the reduced muscle diameter is observed in *tn-/-* muscles supplemented with total yeast extract (**D**) or amino acids (**E**) compared to *tn-/-* muscles alone. (**F**) Scatter plot showing the diameter of muscle VL3 in *WT* or *tn-/-* exposed to the indicated nutritional diets. N ≥ 32. (**G**) Average body mass measurements of *WT* or *tn-/-* L3 larvae. Ten individuals were weighed for each biological replicate that was performed in triplicate. (**H**) Representative pupal cases grown on the indicated diets. (**I**) The axial ratio (length/width) of pupal cases represented by box and whisker plots. N ≥ 10. Mean +/- SD. (\*\*\*\*, p\<0.001; \*, p\<0.05; n.s., not significant). Scale bars: 100 µm (**A-D**, upper panel), 50 µm (**A-D**, lower panel), 1 mm (**H**).](elife-52358-fig5){#fig5}

TRIM32 regulates glycolysis in a diversity of tissues {#s2-4}
-----------------------------------------------------

LDH expression generally correlates with LDH activity and increased glycolytic flux ([@bib63]; [@bib76]). Only a few larval tissues show high LDH activity and exhibit elevated glycolytic rates ([@bib20]; [@bib36]), including muscle and the larval brain ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Since we already established that *tn-/-* muscles were smaller, we wondered if growth of the larval brain also requires TRIM32. The overall size of larval brains dissected from *WT* ([Figure 6A](#fig6){ref-type="fig"}) or *tn-/-* ([Figure 6B](#fig6){ref-type="fig"}) L3 individuals showed a dramatic size difference, whereby loss of TRIM32 reduced the average area of the larval brain by \~40% ([Figure 6G](#fig6){ref-type="fig"}). To determine if a brain-specific reduction in TRIM32 is cell autonomous, we induced two independent *tn RNAi* lines in both neuronal (*elav \>tn RNAi*) and muscle tissue (*mef2 \>tn RNAi*). As expected, reduced larval brain size was observed upon RNAi knockdown of TRIM32 with *elav*-Gal4 ([Figure 6C,D,G](#fig6){ref-type="fig"}), but not with the *mef2* driver ([Figure 6E--G](#fig6){ref-type="fig"}).

![TRIM32 maintains glycolytic-mediated growth in the larval brain.\
(**A--F**) L3 larval brains labeled with DAPI (blue) and F-actin (green). (**A**) A representative micrograph of a *WT* larval brain showing the individual brain lobes (BL) and the ventral nerve cord (VNC). (**B**) The overall size of *tn-/-* brains is reduced due to mutations in *tn*. (**C**) Control brains expressing the pan-neuronal *elav*-Gal4 driver. (**D**) RNAi knockdown of *tn* in neurons under control of the *elav* promoter causes smaller brains. (**E,F**) Expression of *mef2*-Gal4 alone (**E**) or *mef2 \>tn RNAi* in muscle tissue does not alter brain size (**F**). (**G**) Scatter plot depicting the entire brain area (including the BL and VNC) of *WT*, *tn-/-,* Gal4 driver controls, or tissue-specific *tn RNAi* knockdown brains. N ≥ 9. (**H**) Glycolytic rate assay shows a reduction in the proton efflux rate (PER) upon loss of TRIM32 in isolated L3 larval brains. The glycolytic rate is calculated after subtraction of mitochondrial-produced acidification. N = 4. (**I**) Bar graph representing L-lactate levels in isolated larval brain tissue. Only loss of TRIM32 in brain, but not muscle tissue, caused a reduction in L-lactate levels. N ≥ 15. Scale bar: 100 µm (**A--F**). Mean +/- SD. (\*\*\*\*, p\<0.001; \*\*\*, p\<0.01; n.s., not significant).](elife-52358-fig6){#fig6}

Increased biomass accumulation is a primary mechanism for the hypertrophic growth of post-mitotic larval muscles ([@bib16]), while larval brain development requires both cell growth and cell proliferation ([@bib24]). Thus, we wondered whether the TRIM32-mediated reduction in brain size was associated with altered glycolytic activity that reduced cell growth. Two experiments were performed to assess the glycolytic state in larval brain tissue. PER analysis ([@bib51]) of individual larval brains isolated from *tn-/-* showed a reduced glycolytic rate compared to their *WT* counterparts ([Figure 6H](#fig6){ref-type="fig"}). Consistent with reduced substrate flux through the glycolytic pathway, L-lactate levels were also lower in dissected *tn-/-* larval brains ([Figure 6I](#fig6){ref-type="fig"}). Tissue-specific knockdown experiments verified that decreased lactate levels in larval brains resulted from inducing *tn RNAi* in neuronal, but not muscle tissue ([Figure 6I](#fig6){ref-type="fig"}). Next, we assessed how lower glycolytic activity affects overall larval brain size. Defective cell proliferation (assayed by EdU incorporation) or increased cell death (assessed using TUNEL labeling and cleaved-Caspase3 immunoreactivity) did not account for the overall brain size reduction ([Figure 6---figure supplement 1B--I](#fig6s1){ref-type="fig"}). Quantitation of individual brain cell size revealed a marked reduction upon loss of TRIM32 ([Figure 6---figure supplement 1J--M](#fig6s1){ref-type="fig"}) consistent with an increase in cell size as the primary mechanism for TRIM32-mediated tissue growth.

The elevated glycolytic rate that operates in larval muscle and brain tissue is analogous to the Warburg effect in rapidly proliferating cancer cells ([@bib36]; [@bib66]), whereby glucose metabolism is used to synthesize amino acids and other metabolites required for cell growth ([@bib38]; [@bib42]). Thus, we hypothesized that TRIM32 could be a general regulator of highly glycolytic tumor cells. Unlike muscle or brain tissue, neither LDH activity ([@bib72]) nor LDH-GFP expression ([Figure 7A](#fig7){ref-type="fig"}) were detectable in control wing discs, suggesting that this tissue does not exhibit elevated glycolytic activity. Accordingly, loss of TRIM32 did not alter the volume ([Figure 7D](#fig7){ref-type="fig"}) or area ([Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}) of mutant discs compared to *WT* control discs. Moreover, measurements of glycolytic flux using either PER assays ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}) or FILM analysis confirmed that TRIM32-deficient wing discs ([Figure 7F,G](#fig7){ref-type="fig"}) did not show altered glycolytic activity.

![Loss of TRIM32 reduces Pvr-induced glycolytic tumor growth.\
(**A--C**) Either intact (upper panel; red) or isolated (lower panel, blue) wing discs from L3 larvae of the indicated genotypes. LDH-GFP is high in somatic muscles (white arrow). Wing discs are outlined (white dotted outlines). (**A**) The normal size and shape of control *dpp-Gal4/+* wing discs. (**B**) Overexpression of the activated Pvr receptor (*dpp \>Pvr^act^*) causes tissue overgrowth and an increase in LDH-GFP expression (green). (**C**) Tumor growth in a *tn-/-* host is dramatically reduced in size. (**D**) Overall wing disc volumes are represented in this column plot. N ≥ 15. (**E**) Approximately 50% of LDH-GFP(+) cells induced by activated Pvr expression is reduced upon loss of TRIM32. N = 20. (**F**) Representative fluorescence lifetime micrographs of control (*WT* or *tn-/-*) or tumorous (*dpp \>Pvr^act^* or *tn-/-; dpp \>Pvr^act^*) wing discs. (**G**) Box and whisker plot confirms no difference in the glycolytic profile between *WT* or *tn-/-* discs. The decreased lifetime in *dpp \>Pvr^act^* discs, indicative of higher glycolytic flux, is reduced upon loss of TRIM32. N = 6. Mean +/- SD. (\*\*\*\*, p\<0.001; \*, p\<0.05; n.s., not significant). Scale bars: 0.5 mm (A-C, upper panels), 100 µm (A-C, lower panels).](elife-52358-fig7){#fig7}

To examine the possibility that TRIM32 regulates the growth of highly glycolytic tumor cells, we confirmed that overexpression of the activated platelet PDGF/VEGF receptor (Pvr^act^) in *dpp*-expressing wing disc cells increased LDH-GFP expression and promoted tissue overgrowth ([Figure 7B,D](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}; [@bib72]). Remarkably, removal of TRIM32 caused smaller tumors, effectively reducing the overall size of the wing disc ([Figure 7C,D](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Analysis of LDH-GFP expression revealed biological variability as \~50% of TRIM32-deficient wing discs lost LDH-GFP expression ([Figure 7E](#fig7){ref-type="fig"}). FILM analysis validated a decrease in the glycolytic activity of tumors grown in *tn-/-* larvae compared to Pvr-induced tumors in *WT* individuals ([Figure 7F,G](#fig7){ref-type="fig"}). Collectively, our data show that TRIM32 is required for cell growth in both normal and tumorous glycolytic tissues, thus providing a novel molecular explanation for the upregulation of TRIM32 in multiple types of cancer cells.

Discussion {#s3}
==========

A unique feature of *Drosophila* larval development is the inherent glycolytic nature of muscle and brain tissue ([@bib36]; [@bib66]; [@bib68]), which promotes biomass synthesis during this stage of rapid organismal growth. Maintenance of such a high metabolic rate predicts that enzymes are present at sufficient concentrations in the cell to mediate the rapid shunting of intermediates through the pathway ([@bib45]). We show here that TRIM32 directly interacts with and maintains the levels of two glycolytic enzymes. Decreased protein levels of both Ald and Pglym (and possibly other glycolytic enzymes) cripple this rapid flux, effectively blunting the generation of metabolic intermediates that contribute to anabolic synthesis necessary to sustain cell growth ([Figure 8](#fig8){ref-type="fig"}).

![Model for TRIM32 function in the regulation of cell size.\
Biochemical interactions between TRIM32 and glycolytic enzymes such as Ald or Pglym cooperate in maintaining glycolytic activity for the synthesis of macromolecules required for cell growth. Loss of TRIM32 results in reduced levels of glycolytic enzymes, reduced glycolytic pathway intermediates, and compromises cell growth.](elife-52358-fig8){#fig8}

An alternative mechanism that limits cell and tissue growth is nutrient deprivation ([@bib3]). In many organisms, the insulin/target of rapamycin (TOR) pathways integrate nutritional signals to physiologically control body size ([@bib26]). Implicit in this mechanism is the scaling of individual organs. Four pieces of evidence refute nutritional status as a mechanism for TRIM32-mediated tissue growth. First, the overall body size of *tn* mutant pupae is not smaller than their *WT* counterparts under starvation conditions, but instead elongated due to defective muscle contraction ([@bib18]; [@bib32]; [Figure 4G,H](#fig4){ref-type="fig"}; [Figure 5H,I](#fig5){ref-type="fig"}). Second, the size of the wing disc and midgut, both tissues that show reduced growth in poorly fed larvae, is not altered upon loss of TRIM32 ([Figure 7D](#fig7){ref-type="fig"}; [Figure 7---figure supplement 1A--C](#fig7s1){ref-type="fig"}; [Figure 7---figure supplement 2F--H](#fig7s2){ref-type="fig"}). Surprisingly, cellular glucose uptake assayed by the non-metabolizable fluorescent glucose analog 2-\[*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino\]−2-deoxyglucose (2-NBDG), was normal in *tn-/-* larval brains and wing disc-derived tumors ([Figure 7---figure supplement 2A--D](#fig7s2){ref-type="fig"}), demonstrating that glucose is not a limiting substrate for glycolysis in isolated *tn-/-* tissues. Finally, even though systemic effects compromise feeding in *tn-/-* whole larvae ([Figure 7---figure supplement 2E](#fig7s2){ref-type="fig"}), food intake remained constant upon tissue-specific knockdown of TRIM32 in muscle or brains that show reduced tissue growth ([Figure 7---figure supplement 2I,J](#fig7s2){ref-type="fig"}). Collectively, these data demonstrate that TRIM32 functions in a cell autonomous manner to regulate tissue growth, independent of systemic nutritional status.

Li, et al., recently reported that pathways controlling lactate and glycerol-3-phosphate metabolism function redundantly in larval growth ([@bib37]). Removal of LDH and hence lactate production caused an increase in glycerol-3-phosphate, which was sufficient to maintain larval redox balance. Since both LDH and GPDH1 regulate redox balance necessary for maintaining high glycolytic flux to promote biomass accumulation, *Ldh, Gpdh1* double mutants exhibit severe growth defects with reduced brain size. Our results show that loss of TRIM32 decreases both lactate and glycerol-3-phosphate levels ([Figure 3A,B](#fig3){ref-type="fig"}), thus mimicking the reduced carbohydrate metabolism in *Ldh, Gpdh1* double mutants.

It is not clear how mutations in a ubiquitously expressed protein such as TRIM32 result in tissue-specific diseases. One prediction is that TRIM32 differentially interacts with proteins in diverse cell types to elicit distinct biological outputs. There is strong evidence to support this hypothesis in the context of LGMD2H. TRIM32 is upregulated in proliferating satellite cells and loss of this protein prevents myotube regeneration, partially through the misregulation of NDRG and c-Myc ([@bib31]; [@bib46]; [@bib52]; [@bib59]). Muscle-specific targets that contribute to disease progression are less clear. TRIM32-mediated deregulation of key muscle substrates, including actin, α-actinin, tropomyosin, and desmin, contribute to muscle atrophy ([@bib13]; [@bib12]; [@bib30]; [@bib41]), but studies have not been performed to directly test this model in the context of LGMD2H. Interestingly, mammalian glycolytic type II fibers are preferentially affected over oxidative type I fibers in muscle atrophy induced by aging/starvation, as well as in Duchenne's and Becker muscular dystrophies (DMD) ([@bib11]; [@bib54]). *TRIM32 KO* muscles also show a decrease in the glycolytic proteins GAPDH and PyK ([@bib46]), just as we observe a reduction in Ald and Pglym levels in *tn-/-* muscles, suggesting that TRIM32-mediated regulation of glycolysis may be a general mechanism that underlies some muscular dystrophies.

The multi-faceted roles exhibited by TRIM32 in muscle physiology and cancer seem quite different on the surface. However, control of glycolytic flux may be a common mode of regulation that has been overlooked. As in muscle tissue, the majority of studies on TRIM32 and cancer have focused on identifying substrates that are subject to poly-ubiquitination and subsequent proteasomal degradation. Piasy, p53 and Abi2 are known targets of TRIM32 E3 activity that regulate the proliferative balance in cancer cells ([@bib4]; [@bib29]; [@bib39]). The proteolytic turnover of these proteins may affect signaling pathways independent of glycolytic TRIM32 regulation or may be a compensatory mechanism in response to metabolic shifts in which normal cells can transiently adopt cancer-like metabolism during periods of rapid proliferation.

Limitations of this study {#s3-1}
-------------------------

How does this loss of TRIM32 lead to a reduction in glycolytic enzymes? Glycolytic proteins may be substrates for TRIM32 E3 ligase activity. It seems unlikely that TRIM32 polyubiquitinates Ald or Pglym for proteasomal degradation as protein levels are not elevated upon loss of this putative E3 activity. Furthermore, co-immunoprecipitaion of higher molecular weight forms of Ald or Pglym with TRIM32 suggests a yet unidentified post-translational modification. Another possibility, which we favor, is that the NHL domain of TRIM32 serves as a scaffold for the subcellular localization of glycolytic proteins to limit diffusion of substrates during glycolysis. This does not negate, but rather expands the repertoire of TRIM32 functions.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                         Designation                                                            Source or reference                            Identifiers                    Additional information
  (species) or resource                                                                                                                                                                      
  ------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------- ------------------------------ ----------------------------------------------------------------------------------------------------------
  Gene (*Drosophila melanogaster*)      *thin (tn)*                                                            [@bib32]                                       FLYB:FBgn0265356               

  Gene (*D. melanogaster*)              *Aldolase 1 (Ald)*                                                                                                    FLYB:FBgn0000064               

  Gene (*D. melanogaster*)              *Phosphogylcerate mutase 78 (Pglym)*                                                                                  FLYB:FBgn0014869               

  Genetic reagent (*D. melanogaster*)   *w^1118^*                                                              Bloomington *Drosophila* Stock Center (BDSC)   BL3605                         

  Genetic reagent (*D. melanogaster*)   *tnΔA*                                                                 [@bib32]                                                                      

  Genetic reagent (*D. melanogaster*)   *CyO, Tb/Sco*                                                          BDSC                                           BL36335                        

  Genetic reagent (*D. melanogaster*)   *mef-*Gal4                                                             BDSC                                           BL27390                        

  Genetic reagent (*D. melanogaster*)   *elav-*Gal4                                                            BDSC                                           BL458                          

  Genetic reagent (*D. melanogaster*)   *5053*Gal4                                                             BDSC                                           BL2702                         

  Genetic reagent (*D. melanogaster*)   *UAS-tn RNAi-A*                                                        Vienna *Drosophila* Resource Center (VDRC)     v19290                         

  Genetic reagent (*D. melanogaster*)   *UAS-tn RNAi-B*                                                        BDSC                                           BL31588                        

  Genetic reagent (*D. melanogaster*)   *UAS-tn RNAi-C*                                                        VDRC                                           v19291                         

  Genetic reagent (*D. melanogaster*)   *dpp-UAS-mcherry*, *LDH-GFP*                                           [@bib72]                                                                      

  Genetic reagent (*D. melanogaster*)   UAS-*Pvr^act^*                                                         [@bib72]                                                                      

  Genetic reagent (*D. melanogaster*)   *LDH-optGFP*                                                           Materials and methods                                                         

  Genetic reagent (*D. melanogaster*)   UAS-*TRIM32*                                                           [@bib32]                                                                      

  Genetic reagent (*D. melanogaster*)   UAS*-ERR-*FLAG                                                         Materials and methods                                                         

  Antibody                              anti-TRIM32 (guinea pig polyclonal)                                    [@bib32]                                                                      (1:500)

  Antibody                              anti-Pglym (rabbit polyclonal)                                         [@bib61]                                                                      (1:1000) from Jim Vigoreaux

  Antibody                              anti-Ald (rabbit polyclonal)                                           [@bib61]                                                                      (1:1000) from Jim Vigoreaux

  Antibody                              anti-Tm (rat monoclonal)                                               Babraham Institute                             MAC141                         (1:500)

  Antibody                              anti-hALD                                                              Biorad                                         VPA00226                       (1:1000)

  Antibody                              anti-hPGAL1                                                            Cell Signaling                                 D3J9T                          (1:1000)

  Antibody                              anti-ATP5α (mouse monoclonal)                                          Abcam                                          Catalog\# ab14748              (1:10000)

  Antibody                              anti-Cleaved Caspase-3                                                 Cell Signaling                                 Catalog\# 9661                 (1:100)

  Antibody                              Alexa 488 secondaries                                                  Thermo Fisher                                  Catalog\# A12379               (1:400)

  Antibody                              Rabbit IgG HRP Linked Whole Ab                                         GE Healthcare                                  NA934-1ML                      (1:3000-1:5000)

  Antibody                              Mouse IgG HRP Linked Whole Ab                                          GE Healthcare                                  NA931-1ML                      (1:3000-1:5000)

  Recombinant DNA reagent               pGEX-5X-2_TRIM32_NHL                                                   Materials and methods                                                         nucleotides 3231--4062

  Recombinant DNA reagent               pT7HMT_Ald                                                             Materials and methods                                                         His-tagged Ald

  Recombinant DNA reagent               pT7HMT_Pglym                                                           Materials and methods                                                         His-tagged Pglym

  Recombinant DNA reagent               pT7HMT_SCIN                                                            [@bib56]                                                                      His-tagged SCIN

  Sequence-based reagent                pGEX-5X-2_NHL_5'F                                                      Integrated DNA Technologies (IDT)                                             Oligonucleotide GGGATCCCCGGAATTCCCCTGCGCAAGCGCCAGCAGCTGTTC

  Sequence-based reagent                pGEX-5X-2_NHL_5'R                                                      Integrated DNA Technologies (IDT)                                             Oligonucleotide ATAAGAATGCGGCCGCCTGGCGCTTGCGCAGGTACACCTG

  Sequence-based reagent                pT7HMT_Tm2_5'F                                                         Integrated DNA Technologies (IDT)                                             Oligonucleotide ACAGGATCCATGGACGCCATCAAGAAGAAG

  Sequence-based reagent                pT7HMT_Tm2_5'R                                                         Integrated DNA Technologies (IDT)                                             Oligonucleotide AAGGAAAAAAGCGGCCGCTTAGTAGCCAGCCAATTCGGC

  Sequence-based reagent                pT7HMT_Ald_5'F                                                         Integrated DNA Technologies (IDT)                                             Oligonucleotide ACAGGATCCATGACGACCTACTTCAACTACC

  Sequence-based reagent                pT7HMT_Ald_5'R                                                         Integrated DNA Technologies (IDT)                                             Oligonucleotide AAGGAAAAAAGCGGCCGCTCAATACCTGTGGTCATCCAC

  Sequence-based reagent                pT7HMT_Pglym_5'F                                                       Integrated DNA Technologies (IDT)                                             Oligonucleotide CAGGGGTCGACAATGGGCGGCAAGTACAAGATC

  Sequence-based reagent                pT7HMT_Pglym_5'R                                                       Integrated DNA Technologies (IDT)                                             Oligonucleotide AAGGAAAAAAGCGGCCGCTTACTTGGCCTTGCCCTGGGC

  Sequence-based reagent                UAS---2xFLAG-ERR_5'F                                                   Integrated DNA Technologies (IDT)                                             Oligonucleotide AGCGGCCGCCATGGACTACAAGGACGACGATGACAAGGGTGACTACAAGGACGACGATGACAAGGGTATGTCCGACGGCGTCAGCATC

  Sequence-based reagent                UAS---2xFLAG-ERR_3'F                                                   Integrated DNA Technologies (IDT)                                             Oligonucleotide AGCGGCCGCTTATCACCTGGCCAGCGGCTCGAGC

  Commercial assay or kit               ATP Determination Kit                                                  Molecular Probes                               Catalog\# A22066               

  Commercial assay or kit               Bradford Assay kit                                                     Bio-Rad                                        Catalog\# 5000001              

  Commercial assay or kit               RNAeasy Mini Kit (50)                                                  Qiagen                                         Catalog\# 74104                

  Commercial assay or kit               DeadEnd Fluorometric TUNEL System                                      Promega                                        Catalog\# G3250                

  Commercial assay or kit               Click-iT EdU Cell Proliferation Kit for Imaging, Alexa Fluor 488 dye   Thermo Fisher                                  Catalog\# C10337               

  Commercial assay or kit               ECL Plus Western Blotting Detection kit                                Thermo Fisher                                  Catalog\# 32132                

  Commercial assay or kit               SuperScript VILO cDNA Synthesis Kit                                    Invitrogen                                     Catalog\# 11754050             

  Commercial assay or kit               EnzyChromTM L-Lactate Assay Kit                                        BioAssay Systems                               Catalog\# ECLC-100             

  Commercial assay or kit               Power UP SYBR Green Master mix                                         Applied Biosystems                             Catalog\# A25741               

  Chemical compound, drug               DAPI (4′,6-diamidino-2-phenylindole, Dihydrochloride)                  Thermo Fisher                                  Catalog\# D1306                

  Chemical compound, drug               2-NBDG                                                                 Cayman Chemicals                               Catalog\# 186689-07-6          

  Chemical compound, drug               Erioglaucine disodium salt                                             Milipore Sigma                                 Catalog\# 861146               

  Chemical compound, drug               Formaldehyde, 16% Methanol-free, ultra-pure EM Grade                   Polyscience                                    Catalog\# 1881lawr4            

  Chemical compound, drug               Triton X-100                                                           Sigma-Aldrich                                  Catalog\# 9002-93-1            

  Chemical compound, drug               Tween20                                                                Sigma-Aldrich                                  Catalog\# 9005-64-5            

  Chemical compound, drug               Glycerol                                                               Fisher                                         Catalog\# BP229-1              

  Chemical compound, drug               Methanol                                                               Fisher                                         Catalog\# A412P-4              

  Chemical compound, drug               Bromophenol-blue                                                       Amresco                                        Catalog\# 0449--25G            

  Chemical compound, drug               DTT (1,4-Dithiothreitol)                                               Sigma-Aldrich                                  Catalog\# 3483-12-3            

  Chemical compound, drug               Tris base                                                              Fisher                                         Catalog\# BP152-5              

  Chemical compound, drug               Sodium Chloride                                                        Fisher                                         Catalog\# BP358-212            

  Chemical compound, drug               Hydrochloric acid                                                      Fisher                                         Catalog\# A144-50/A144S212     

  Chemical compound, drug               Potassium Chloride                                                     Fisher                                         Catalog\# BP366-500            

  Chemical compound, drug               Magnesium Chloride                                                     Fisher                                         Catalog\# M-33                 

  Chemical compound, drug               Sodium Bicarbonate                                                     Fisher                                         Catalog\# S233-500             

  Chemical compound, drug               Calcium Chloride Dihydrate                                             Fisher                                         Catalog\# C-79                 

  Chemical compound, drug               Sodium Dodecyl Sulphate                                                Fisher                                         Catalog\# BP166-500            

  Chemical compound, drug               Sucrose                                                                Fisher                                         Catalog\# S3-500               

  Chemical compound, drug               Agar,Powder/Flakes                                                     Fisher Scientific                              Catalog\# BP1423-500           

  Chemical compound, drug               L-amino acids                                                          Sigma-Aldrich                                  Catalog\# 200-157-7            

  Chemical compound, drug               Yeast Extract Hy-Yest 412                                              Kind gift from Dr. Lawrence Davis              N/A                            

  Chemical compound, drug               HEPES                                                                  Fisher                                         Catalog\# BP310-100            

  Chemical compound, drug               TEMED                                                                  Santa Cruz                                     Catalog\# SC-29111             

  Chemical compound, drug               Ammonium Persulfate                                                    Fisher                                         Catalog\# BP179-100            

  Chemical compound, drug               HisPur Ni-NTA Magnetic Beads                                           Thermo Fisher                                  Catalog\# 88831                

  Chemical compound, drug               Cyanogen bromide activated Sepharose 4B                                Sigma-Aldrich                                  Catalog\# 68987-32-6           

  Software, algorithm                   Graphpad Prism 7.00                                                    GraphPad Software                              <https://www.graphpad.com/>    

  Software, algorithm                   ImageJ                                                                 NIH                                            <https://imagej.nih.gov/ij/>   

  Software, algorithm                   Adobe Photoshop                                                        Adobe                                          N/A                            

  Software, algorithm                   Zen black                                                              Zeiss                                          N/A                            

  Other                                 Zeiss 700 confocal microscope                                          Zeiss                                          N/A                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fly genetics {#s4-1}
------------

Fly stocks were reared on standard cornmeal media at 25°C unless otherwise indicated. The *WT* control strain was *w^1118^* \[Bloomington (BL) *Drosophila* Stock Center; BL3605). The *tnΔA* mutation ([@bib32]) was maintained over the *CyO, Tb/Sco* (BL36335) balancer chromosome. Non-Tb individuals from the *tnΔA/CyO, Tb^1^* stock were used for *tn-/-* analysis. The following Gal4 and/or RNAi lines were used: *mef2*-Gal4 (BL27390), *elav*-Gal4 (BL458), *5053*-Gal4 (BL2702), UAS-*tn RNAi-A* \[Vienna *Drosophila* Resource Center (VDRC); v19290), UAS-*tn RNAi-B* (BL31588), and UAS-*tn RNAi-C* (v19291). UAS-*TRIM32* was previously described ([@bib32]). The *UAS-2XFLAG-dERR* transgene was generated by amplifying the *dERR* cDNA using the oligos listed in [Table 1](#table1){ref-type="table"}. The resulting PCR product was sequenced, inserted into the NotI site of pUAST-attP, and injected to a strain containing the attP40 site by BestGene Inc (Chino Hills, CA). The transgenic *dpp-Gal4, UAS-mCherry, LDH-GFP* and *UAS-Pvr^act^* flies were a kind gift from U. Banerjee ([@bib72]). The *LDH-GFP* line ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}) was generated using a previously described *pLdh* genomic rescue construct ([@bib36]). Briefly, GFP was inserted at the 3' end of the *Ldh* coding region using a PCR based method. The plasmid was injected into the strain attP40w by Rainbow Transgenics (Camarillo, CA) and the F1 generation was screened for transgene integration at the attP40 docking site. This transgene is capable of rescuing the *Ldh* mutant larval lethal phenotype (Chawla and Tennessen, in preparation).

###### Statistics Summary.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Panel                                                          Graph type             N value                                                                                                   Statistical test used                        Precision      p-value
  -------------------------------------------------------------- ---------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------- -------------- --------------------------------------
  [Figure 2E,F](#fig2){ref-type="fig"}                           Bar graphs             Pool of 5 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)                Unpaired t-test                              Mean +/- SD    p\<0.05

  [Figure 3A](#fig3){ref-type="fig"}                             Volcano plot           Pool of 25 larvae per genotype (N = 6 biological replicates)                                              Univariate fold change and t-test analysis   N/A            FC \> 1.5\
                                                                                                                                                                                                                                                              p\<0.05

  [Figure 3B](#fig3){ref-type="fig"}                             Box and whisker plot   Pool of 25 larvae per genotype (N = 6 biological replicates)                                              Unpaired t-test                              Min to max     p\<0.05

  [Figure 3G](#fig3){ref-type="fig"}                             Scatter plot           N ≥ 8                                                                                                     One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001, p\<0.01

  [Figure 3H](#fig3){ref-type="fig"}                             Bar graph              N = 4                                                                                                     Unpaired t-test                              Mean +/- SD    p\<0.05

  [Figure 3I](#fig3){ref-type="fig"}                             Mean and error plot    N = 4                                                                                                     Holm-Sidak t-test                            Mean +/- SEM   p\<0.05

  [Figure 3J](#fig3){ref-type="fig"}                             Box and whisker plot   N = 5                                                                                                     Unpaired t-test                              Min to max     p\<0.05

  [Figure 4D](#fig4){ref-type="fig"}                             Scatter plot           N ≥ 10                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001

  [Figure 4E](#fig4){ref-type="fig"}                             Bar graph              Pool of at least eight larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)   One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.005, p\<0.01, n.s.

  [Figure 4F](#fig4){ref-type="fig"}                             Scatter plot           N ≥ 10                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001

  [Figure 4H](#fig4){ref-type="fig"}                             Box and whisker plot   N = 10                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001

  [Figure 4I,J](#fig4){ref-type="fig"}                           Bar graph              Pool of 5 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)                One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001, p\<0.005, p\<0.05, p\<0.01

  [Figure 5A](#fig5){ref-type="fig"}                             Box and whisker plot   Pools of 25 larvae (N = 6 biological replicates)                                                          Unpaired t-test                              Min to max     p\<0.05

  [Figure 5F](#fig5){ref-type="fig"}                             Scatter plot           N ≥ 32                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.05, p\<0.001, n.s.

  [Figure 5G](#fig5){ref-type="fig"}                             Column graph           Pool of 10 larvae per genotype subjected to each condition (N = 3)                                        One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.05, p\<0.001, n.s.

  [Figure 5I](#fig5){ref-type="fig"}                             Box and whisker plot   N ≥ 10                                                                                                    One-Way ANOVA Kruskal-Wallis test            Min to max     p\<0.001

  [Figure 6G](#fig6){ref-type="fig"}                             Scatter plot           N ≥ 9                                                                                                     One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001, n.s.

  [Figure 6H](#fig6){ref-type="fig"}                             Mean and error plot    N = 4                                                                                                     Holm-Sidak t-test                            Mean +/- SEM   p\<0.05

  [Figure 6I](#fig6){ref-type="fig"}                             Bar graph              Pool of at least 15 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)      One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.005, p\<0.01, n.s.

  [Figure 7D](#fig7){ref-type="fig"}                             Scatter plot           N = 15                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001, p\<0.05, n.s.

  [Figure 7E](#fig7){ref-type="fig"}                             Bar graph              N = 20                                                                                                    Unpaired t-test                              Mean           N/A

  [Figure 7G](#fig7){ref-type="fig"}                             Box and whisker plot   N = 6                                                                                                     One-Way ANOVA Kruskal-Wallis test            Min to max     p\<0.05, n.s.

  [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}     Bar graph              Pool of 5 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)                Unpaired t-test                              Mean +/- SD    p\<0.05

  [Figure 2---figure supplement 1F,G](#fig2s1){ref-type="fig"}   Bar graph              Pool of 5 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)                Unpaired t-test                              Mean +/- SD    n.s.

  [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}     Box and whisker plot   N = 6 chambers with five larvae per genotype                                                              Unpaired t-test                              Min to max     p\<0.05

  [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}     Bar graph              Pool of 25 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)               Unpaired t-test                              Mean +/- SD    p\<0.001

  [Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}     Scatter plot           N ≥ 9                                                                                                     Unpaired t-test                              Mean +/- SD    n.s.

  [Figure 6---figure supplement 1M](#fig6s1){ref-type="fig"}     Scatter plot           N \> 300 cells measured in 10 brains of each genotype                                                     Unpaired t-test                              Mean +/- SD    p\<0.001

  [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}     Scatter plot           N ≥ 20                                                                                                    One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.001, n.s.

  [Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}     Mean and error plot    N = 10                                                                                                    Holm-Sidak t-test                            Mean +/- SEM   n.s.

  [Figure 7---figure supplement 2E](#fig7s2){ref-type="fig"}     Bar graph              N = 9                                                                                                     Unpaired t-test                              Mean +/- SD    p\<0.005

  [Figure 7---figure supplement 2H](#fig7s2){ref-type="fig"}     Scatter plot           N = 8                                                                                                     Unpaired t-test                              Mean +/- SD    n.s.

  [Figure 7---figure supplement 2J](#fig7s2){ref-type="fig"}     Bar graph              Pool of at least 15 larvae per genotype (N = 3 biological replicates and N = 3 technical replicates)      One-Way ANOVA Kruskal-Wallis test            Mean +/- SD    p\<0.05, n.s.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Immunostaining and microscopy {#s4-2}
-----------------------------

*Muscle*. Synchronized L2 or wandering L3 larvae were rinsed with 0.7% (w/v) NaCl/0.1% Triton, filleted in ice cold 1X PBS on Sylgard plates, and fixed in 4% (v/v) formaldehyde (Fisher) followed by three washes with 0.5% PBT. Phalloidin 488 or 594 was used to label F-actin (1:400, Molecular Probes). *Other tissues*. Wing discs, larval brains, or midguts were isolated from wandering L3 larvae and fixed for 25 min in 4% formaldehyde in PBS. Both discs and brains were stained overnight with DAPI (1:400) at 4°C. Midguts were stained with Phalloidin 488 (1:400, Molecular Probes). Anti-Caspase-3 (1:100, Cell Signaling Technology, Danvers, MA) staining on brains was performed overnight at 4°C followed by labeling with Alexa Fluor anti-rabbit 568 secondary antibody (1:400). Either muscle fillets, isolated brains or wing discs were mounted in anti-fade mounting medium (190% glycerol, 0.5% n-propyl gallate in 20 mM Tris buffer, pH = 8.0) and imaged using a Zeiss 700 confocal microscope.

Molecular biology {#s4-3}
-----------------

The NHL region of *Drosophila* TRIM32 (nucleotides 3231--4062) was PCR amplified using Phusion polymerase (ThermoFisher Scientific), digested with EcoRI and NotI, and ligated into the pGEX-5X-2 expression vector containing an N-terminal GST tag. Tm2, Ald, and Pglym were amplified by PCR and subcloned into the pT7HMT protein expression vector with either SalI/NotI or BamHI/NotI. Primers used for PCR amplification are included in [Table 1](#table1){ref-type="table"}.

Protein expression and purification {#s4-4}
-----------------------------------

Protein expression was performed in *E. coli* BL21 cells. A single colony was inoculated into 100 mL of LB media supplemented with the appropriate antibiotic at 37°C, incubated overnight and then diluted into 1L of Terrific Broth. Protein expression was induced at OD~600~ = 0.6 after the addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM ([@bib22]). After 18 hr of incubation at 18°C, cells were centrifuged and were lysed using a microfluidizer for cell lysis. After centrifugation, the GST_TRIM32_NHL tagged protein was purified using GST affinity chromatography (GE Healthcare), further purified using size exclusion and ion-exchange Chromatography, and concentrated using 30K Amicon centrifuge columns (Millipore). The large scale expression and purification of Tm2, Ald, and Pglym was similar but used Ni^2+^ column for the initial purification step for His-tag binding. The purified proteins were stored at −80°C until use.

Crystallization, X-ray diffraction, structure solution, and refinement {#s4-5}
----------------------------------------------------------------------

Crystals of a recombinant form of the NHL-repeat region of *Drosophila* TRIM32 were obtained by vapor diffusion of hanging drops. Briefly, a sample of purified protein was buffer exchanged into double-deionized water and concentrated to 5 mg/ml. Crystals were obtained from 2 µl droplets that had been established by mixing 1 µl of protein with 1 µl of precipitant solution \[0.1M HEPES (pH 7.8), 0.2 M NaCl, and 25% (v/v) PEG-3350\] and incubating over 500 µl of precipitant solution at 20°C. Rod-shaped crystals appeared within 2--3 days and grew to their full size within 1--2 weeks. Single crystals were harvested and briefly soaked in a cryopreservation buffer consisting of precipitation solution supplemented with an additional 20% (v/v) glycerol. Monochromatic X-ray diffraction data were collected at beamline 22-BM of the Advanced Photon Source at Argonne National Laboratory using incident radiation of λ = 1.000 Å. Reflections were indexed, integrated, and scaled using the HKL2000 software suite ([@bib53]). Initial phases were obtained by molecular replacement using program PHASER ([@bib44]) and a poly-alanine model derived from chain A of PDB entry 1Q7F. The model was constructed and refined through an iterative process consisting of automated building and refinement in PHENIX ([@bib1]; [@bib79]), coupled with manual inspection and modifications. The final model consists of 292 protein residues, 85 ordered solvent molecules, and six ligand molecules. 94% of the protein residues occupy favored regions in the Ramachandran plot, with an additional 4% in allowed regions. Additional information on data collection and model statistics may be found in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. The final model and structure factors have been deposited in the PDB under accession code 6D69.

Mass spectrometry (MS) analysis {#s4-6}
-------------------------------

L3 larvae were homogenized in lysis buffer \[50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10% (v/v) glycerol and 1 mM EDTA\] plus inhibitors \[1 mM Na3VO4, 5 mM NPPS, 2 mM PMSF, 2 ug/ml Leupeptin, 10 µM MG132, 1x Halt Pro inhibitor cocktail (Roche)\]. 10 µg of purified TRIM32_NHL protein was coupled to Cyanogen bromide-activated-Sepharose 4B beads (Sigma-Aldrich), incubated for 2 hr at 4°C with 100 mg of lysates prepared from L3 larvae. Bead-protein complexes were washed 3X with wash buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA and 1% (v/v) Triton\]. Control pulldowns were performed using beads alone. Beads containing protein complexes were sent to Oklahoma State University for MS analysis. Statistical analysis was performed using Perseus MaxQuant ([@bib15]; [@bib70]).

In vitro binding assay {#s4-7}
----------------------

To assess the interaction with TRIM32_NHL, 10 µg of purified candidate proteins (Tm2, Ald or Pglym) or the negative control (SCIN) were immobilized on Ni^2+^-NTA magnetic beads (ThermoFisher Scientific) for 1.5 hr followed by incubation with 10 µg of dTRIM32 NHL for 30 min at 4°C on a rotating platform. The complexes were washed 6x \[300 mM NaCl, PBS (pH = 7.0) + 1% (v/v) Triton\]. The bound proteins were eluted by boiling at 100°C in 6X Laemmli buffer for 10 min. The binding was analyzed on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions followed by Coomassie Blue Staining.

Co-Immunoprecipitation {#s4-8}
----------------------

For lysate preparation, *WT* third-instar larvae were homogenized in lysis buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10% glycerol, 1% Triton, 1 mM EDTA) containing 1X Halt Protease Inhibitor (Thermo fisher Scientific) and 10 μM MG132. The lysate was precleared via centrifugation at 13,000 x for 20 min at 4^◦^C and the resulting protein concentration was measured using the Bradford Assay (Biorad, Hercules, CA). 500 μg of the lysate was set aside for input analysis. For immunoprecipitations, 20 μL of Protein A Sepharose 4b beads (Thermo Fisher Scientific) were washed twice with the lysis buffer. The beads were then incubated with 15 μg of *Drosophila* anti-TRIM32 antibody overnight at 4°C. The antibody conjugated beads were then mixed with 2 mg of lysate and incubated for 2 hr at 4^◦^C on a rotating wheel. Post incubation, the resin was centrifuged at 1000 x g for 3 min washed five times with wash buffer (1M NaCl, 1%Triton, PBS). 30 μL of 6X Laemmli buffer was used to elute bound proteins off the resin and these samples were denatured by heating at 100°C for 10 min. Eluted protein samples were subjected to 10% SDS PAGE gel electrophoresis and transferred to polyvinyl difluoride (PVDF) membranes (Pierce Biotechnology, Inc, Waltham, MA) for Western blotting with the following primary antibodies: rabbit anti-*Drosophila* Ald \[1:1000, ([@bib61]), rabbit anti- *Drosophila* Pglym \[1:1000, ([@bib61]), guinea pig anti-*Drosophila* TRIM32 \[1:500, ([@bib32]), rabbit anti-human ALD \[1:1000, Biorad, Hercules, CA\], rabbit anti-human PGAM1 \[1:1000, Cell Signaling, Danvers, MA\]. Post-treatment with the primary antibodies, blots were washed thoroughly with the wash buffer (TBS+ 0.1%Tween) and incubated with HRP conjugated and fluorescent secondary antibodies (dilution 1:5000) for 2 hr at room temperature. Protein detection was performed using the Prometheus ProSignal Pico western blotting detection kit (Genesee Scientific).

Metabolomics analysis {#s4-9}
---------------------

Pooled *WT* or *tn-/-* L3 larvae (25 each) were selected and washed with NaCl/0.1% Triton to remove food or debris. Each batch of pooled larvae were flash frozen in liquid nitrogen and sent to the University of Utah Metabolomics Core. Metabolites were extracted and derivatized before gas chromatography-mass spectrometry (GC-MS) analysis with an Agilent 5977B GC-MS. Data was collected using MassHunter software and metabolite identity was determined using MassHunter Quant. The metabolite data was normalized to standards, parsed, and Metaboanalyst 3.0 was used for statistical analysis and data processing. Independently, groups of 10 larvae were weighed on an analytical scale to determine the difference in body mass between *WT* and mutant cohorts before analysis. Six biological replicates were performed for each genotype.

In vivo feeding assays {#s4-10}
----------------------

To assess the impact of amino acid supplements on muscle mass in *WT* and *tn-/-,* embryos were reared from hatching until analysis at the L3 stage at 25°*C* on three different food conditions in 60 mm petri dishes: (1) Agar only control: 2.25% (w/v) agar in distilled water; (2) Yeast extract powder (mixture of amino acids, carbohydrates, peptides and soluble vitamins): 15% (w/v) yeast extract powder added to 2.25% (w/v) agar; or (3) Amino acids: 20 individual amino acids were individually weighed and added to 2.25% (w/v) agar ([@bib35]). Both *WT* and *tn-/-* L3 larvae were dissected, stained with phalloidin, and analyzed using confocal microscopy for each condition. Note that agar contains two polysaccharides, agarose and agaropectin. Thus, the larvae are starved, but not completely devoid of nutrients.

ATP assay {#s4-11}
---------

25 L3 larvae were pooled and homogenized in 100 µl of extraction buffer \[6 M guanidine HCL, 100 mM Tris (pH 7.8), 4 mM EDTA\], boiled for 5 min, and centrifuged at 13,000 x g for 5 min at 4°C. Protein concentrations were measured using the Bradford Assay kit (Biorad, Hercules, CA). ATP levels were determined using an ATP Determination Kit (Molecular Probes) as described in [@bib65]. 100 µl assays were performed in a 96 well plate and the luminescence was measured using Perkin Elmer EnSpire Multimode plate reader. Each sample was processed in triplicate and read in triplicate. The amount of ATP was normalized to total protein concentration.

Quantitation and statistical analysis {#s4-12}
-------------------------------------

*Muscle diameter measurements.* Z-stack images for each fillet were converted to a maximum intensity projection. The Polylines plugin from ImageJ was used to measure the muscle width of all VL3 muscles from dissected L2 and L3 individuals. *Pupal case axial ratio determination.* Pupa of the appropriate genotype were removed from vials, oriented dorsal side up, and attached to slides using a small drop of nail polish. Images were taken with a Leica M165 FC Stereomicroscope. Length and width measurements for each pupae were performed in ImageJ using the line and measure functions. Values were put into an Excel spreadsheet and the axial ratio (length/width) was calculated for each individual. The raw data was imported into Graphpad Prism 6.0 and graphed as a box and whiskers plot. N ≥ 10 for each genotype. *Brain and midgut analysis.* Z-stack images of isolated brain or midgut tissue areas were measured in ImageJ using the outline and measure functions N ≥ 8 for each genotype. Brain lobe cell size was determined using the analyze particle function after thresholding in ImageJ. N \> 300 cells in 10 individual brain lobes for each genotype. *Larval mass measurements.* For each genotype and condition tested, pools of 10 larvae weighed on a digital scale. The average of each pool (N = 3) was plotted. *Wing disc-associated tumor analysis*. Z-stack images of each wing disc were used to measure the area and volume. For area measurements, the single plane that contained the maximum area for each disc was fully outlined using the free draw tool followed by the measure command in ImageJ. For volume quantitation, each disc in each Z-section was outlined, subjected to thresholding, and the stack command was used to measure the stacked volume. *Statistics.* Raw data was imported to GraphPad Prism 6.0 for statistical analysis and graph generation. All error bars represent mean ± standard deviation (SD). Statistical significances were determined using either student t-tests, Mann-Whitney tests or one-way ANOVA. Differences were considered significant if p\<0.05 and are indicated in each figure legend.

Western blots {#s4-13}
-------------

Five whole L3 larvae were homogenized in 3X SDS sample buffer \[188 mM Tris-HCl (pH 6.8), 3% (w/v) SDS, 30% (v/v) glycerol, 0.01% (w/v) bromophenol-blue, and 15% (v/v) β-mercaptoethanol\], boiled at 95°C for 10 min, and centrifuged at 15,000 x g to remove cellular debris. To analyze overall protein levels, lysates were subjected to SDS--PAGE, transferred to polyvinyl difluoride (PVDF) membranes (Pierce Biotechnology, Inc, Waltham, MA), and probed with the appropriate primary antibodies: rabbit-Pglym \[1:1000, ([@bib61])\], rabbit-Ald, \[1:1000, ([@bib61])﻿\], rat-Tm (1:500, Babraham Institute, Cambridge, UK) and mouse anti-ATPase 5α (1:10000, Abcam, Cambridge, MA). Horseradish Peroxidase (HRP) conjugated secondary antibodies (1:3000--1:5000, GE Healthcare, Chicago, IL) were used to detect primary antibodies. Protein detection was carried out using the ECL Plus western blotting detection kit (ThermoFisher Scientific, Waltham, MA). Densitometry analysis was performed by calculating the relative band intensities of candidate proteins to ATPase 5α loading control using ImageJ software.

Quantitative PCR (qPCR) {#s4-14}
-----------------------

RNA was isolated from a pool of five whole L3 larvae for each genotype using the RNAeasy Mini Kit (QIAGEN, Valencia, CA). After elution, RNA concentrations were determined and single strand complementary DNA (cDNA) was synthesized from 100 ng of RNA using the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). For qPCR, each cDNA sample was diluted to 1:50 and mixed with Power UP SYBR Green Master mix also mixed with the appropriate primers (Applied Biosystems, Foster City, CA). *rp49* was used as the reference gene. Primers were synthesized by Integrated DNA Technologies (IDT):

1.  *rp49*: F5';-GCCCAAGGGTATCGACAACA-3', R5'-GCGCTTGTTCGATCCGTAAC-3'

2.  *Ald*: F5'- GGCCGCCGTCTACAAGGC-3', R5'-GTTCTCCTTCTTGCCAGC-3'

3.  *Pglym78:* F5-AGTCCGAGTGGAACCAGAAGA-3', R5'-GGCTTGAAGTTCTCGTCCAG-3'

Three independent biological replicates were processed for each genotype and reactions were run in triplicate using the Quant Studio 3 Applied Biosystem with Quant studio design and analysis software. The average of the triplicates was used to calculate the 2-ΔΔCt values (normalized fold expression). Quantification of mRNA levels between different genotypes at the same time point was performed using the student t-test.

Agilent seahorse XFe96 analyzer experiments {#s4-15}
-------------------------------------------

*Larval brain, muscle, and wing disc preparation.* The Agilent Seahorse XFe96 metabolic analyzer was placed in an incubator set to 12°C, and analyzer was set to 25°C with the heat on (running Wave software version 2.4). An Agilent Seahorse XFe96 cartridge (Agilent, Santa Clara, CA) was hydrated with 200 μl of calibrant solution (Agilent, Santa Clara, CA) overnight at 25°C. The next day, brains, muscles, or discs were dissected in phosphate buffered solution (PBS) and added to an Agilent 96-well cell plate (Agilent, Santa Clara, CA) containing 50 μl of Agilent Seahorse assay media with supplements required for specific assay (see glycolytic rate assay method). Tissue was sunk to the bottom of the well and centered in the middle between the three raised spheres. Forceps were used to lower the tissue restraint such that the plastic ring is facing toward the bottom of the well and the nylon screen is facing the top of the well. A probe was used to gently push the edge of the tissue restraint down toward the bottom of the well until the restraint did not move or float in the well. 130 μl of assay media was added to each well; resulting in a total of 180 μl final in each well. The cell plate was placed on the tray of the XFe96 analyzer. The instrument was for basal and glycolytic rate assays with all cycle procedures consisting of one-minute mixing, zero-minutes waiting, and 3-min measuring. *Basal ECAR measurements using the XFe96.* Basal levels of extracellular acidification (ECAR) were measured for a minimum of six cycles. Tissue restraints were measured without tissue as a control. Agilent Seahorse XF assay medium (Agilent, Santa Clara, CA) supplemented with 10 mM glucose, and 10 mM sodium pyruvate was used for all basal measurement assays. A minimum of 4 biological replicates were used to analyze the basal rate of *WT* and *tn-/-* larval muscle. Standard error of the mean (SEM) was used in analyzing metabolic measurement levels. Statistical significance was determined using the Holm-Sidak method with alpha = 0.05. *Glycolytic Rate Assay.* Analysis of glycolytic rate with mitochondrial-produced acidification subtracted was conducted using base medium without phenol red (Agilent, Santa Clara, CA), supplemented with 5 mM Hepes (Agilent, Santa Clara, CA), 2 mM glutamine, 10 mM glucose and 1 mM sodium pyruvate. 20 μl of 50 μM rotenone and antimycin-A was added to port A and injected at the 7th cycle, resulting in a final concentration of 5 μM rotenone and antimycin-A. 22 μl of 1M 2-deoxyglutarate (2-DG) was added to port B and injected at the 12th cycle, resulting in a final concentration of 100 mM 2-DG. The software package included with this kit analyzes the oxygen consumption and extracellular acidification rates, while factoring in the buffer capacity of the media. It also calculates the acidification caused by the mitochondria and subtracts this from the data. This method produces the proton efflux rate (PER). A minimum of four biological replicates were used to analyze the glycolytic rate of *WT* and *tn-/-* larval brains. Standard error of the mean (SEM) was used in analyzing metabolic measurement levels. Statistical significance was determined using the Holm-Sidak method with alpha = 0.05. *Normalization of XFe96 measurements by protein concentration*. XFe96 analysis data was normalized by protein concentration. Protein normalization was conducted using the Pierce 660 nm protein assay reagent (Thermo Fisher Scientific, Waltham, MA). Each sample was homogenized in default lysis buffer (50 mM Tris (pH 7.5), 125 mM NaCl, 5% glycerol, 0.2% IGEPAL, 1.5 mM MgCl~2~, 1 mM DTT, 25 mM NaF, 1 mM Na~3~VO~4~, 1 mM EDTA and 2 × Complete protease inhibitor (Roche, Indianapolis, IN) on ice, incubated on ice for 15 min, and centrifuged at full speed for 15 min at 4°C. Supernatant was collected and measured as indicated in the Pierce 660 nm protein assay reagent manual. Samples were assayed using a Biotek Cytation three plate reader. PER and muscle ECAR values were divided by μg amount of protein measured to determine the normalized pmol/min/μg rate of proton efflux and mpH/min/μg rate of extracellular acidification. Standard error of the mean (SEM) was used in analyzing metabolic measurement levels. Statistical significance was determined using the Holm-Sidak method with alpha = 0.05.

Respirometry {#s4-16}
------------

Larval metabolic rates were assessed by indirect calorimetry, measuring CO2 production with flow-through respirometry using the Multiple Animal Versatile Energetics platform for metabolic phenotyping (MAVEn, Sable Systems International, Las Vegas, NV). Baseline ultra zero air was provided from a compressed air cylinder and regulated at approximately 20 mL/min through each of 16 respirometry chambers simultaneously. Larvae were measured in groups of five in each chamber. The MAVEn automated flow switching between chambers and baseline (interleave ratio 16:1; dwell time per chamber 2 min). Differential carbon dioxide concentration was measured with a LiCor 7000 infrared gas analyzer. The wet mass of insects prior to and following respirometry was measured to the nearest 0.01 mg (Mettler Toledo XS22SDU Analytical Balance). N = 6 chambers with five larvae in each chamber for each genotype.

FLIM {#s4-17}
----

The multiphoton based ([@bib17]) lifetime and intensity imaging was performed on a custom multiphoton laser scanning system built around an inverted Nikon Eclipse TE2000U at the Laboratory for Optical and Computational Instrumentation ([@bib74]). A 20x air immersion objective (Nikon Plan Apo VC, 0.75 NA) (Melville, NY, USA) was used for all imaging. For NADH imaging, data was collected using an excitation wavelength of 740 nm, and the emission was filtered at 457 ± 50 nm (Semrock, Rochester, NY) for the spectral peak for NADH/NADPH. For intensity imaging, the excitation was set at 980 nm, and an emission 520 ± 35 filter was used (Semrock, Rochester, NY). The FLIM fitting process was done according to the methods sections describing FLIM analysis performed for the same scope ([@bib23]). For each sample, around eight neighboring fields were randomly selected, and the average value of lifetime and free NADH ratio were calculated.

L-lactate assays {#s4-18}
----------------

L-lactate levels in the brain and muscle were measured in the indicated genotypes. L3 larval brains and muscle carcasses were dissected and placed in ice-cold 1X PBS. Brains (n = 20 each, total 60 brains per genotype) or muscle tissue (N = 8, total 24 carcasses per genotype) were pooled together and homogenized in 50 μL 1X PBS. Bradford Assay was used to quantitate protein concentrations. Each lysate was transferred to a 96-well plate and incubated with lactate dehydrogenase and NAD/MTT for 2 hr at room temperature (EnzyChrom Glycolysis Assay Kit, BioAssay Systems). The intensity of the reduced dye was measured at 565 nm, which is directly proportional to the concentration of the L-Lactate in the sample.

EdU incorporation assay {#s4-19}
-----------------------

Dissected larval brains were incubated in *Drosophila* Schneider\'s medium containing 10 uM EdU (ThermoFisher Scientific, Waltham, MA) for 2 hr at room temperature. Tissues were fixed and Click-iT EdU staining was performed according to the manufacturer's protocol. For quantification, images of the whole larval brain were captured using a Zeiss 700 confocal microscope. ImageJ was used to manually count the number of EdU positive cells.

Glucose uptake assay {#s4-20}
--------------------

Wandering L3 larvae of the following genotypes (*dpp*-Gal4 UAS-mCherry, UAS-*LDH*GFP \>UAS Pvr^act^, *tn-/-; dpp*-Gal4 UAS-mCherry, UAS-*LDH*GFP \>UAS Pvr^act^) were placed in *Drosophila* HL3 buffer (NaCl 70 mM, KCl 5 mM, CaCl~2~1.5 mM, MgCl~2~20 mM, NaHCO~3~10 mM, trehalose 5 mM, sucrose 115 mM, and Hepes 5 mM (pH 7.2) on ice. Wing discs were dissected in ice cold PBS followed by incubation with 2-NBDG (2.5 mg/mL, Cayman Chemical, Ann Arbor, MI) for 15 min at room temperature. The tissues were washed with 1X PBS twice, fixed and imaged. Similarly, for analyzing glucose uptake in larval brain, *WT* and *tn-/-* mutant brains were dissected and incubated with 2-NBDG as indicated above.

Food intake assay {#s4-21}
-----------------

Approximately 15--35 early L3 larvae of the indicated genotypes were fed on yeast paste with 0.16% Erioglaucine dye for 24 hr ([@bib2]). Post feeding larvae were pooled together and washed thrice with distilled water. The pooled larvae were homogenized in 250 μL of ddH~2~O, centrifuged at 15,000 rpm for 20 min. 225 μL of supernatant was carefully transferred to a 1.5 mL tube containing 50 μL 100% ethanol and centrifuged for 10 min. 250 μL of the supernatant was placed in a new tube and centrifuged again for 5 min. Following centrifugation, 200 μL of the supernatant was placed in a 96-well crystal plate and the OD was measured at 633 nm. Three groups of 15 larvae of each genotype were analyzed.

TUNEL assay {#s4-22}
-----------

For TUNEL labeling, fixed brains were treated with 20 µg/mL Proteinase K in PBS for 20 min. For positive control, *WT* brains were incubated with 100 µl of DNase (1 U/ µl) for 10 min at room temperature post Proteinase K treatment. The tissues were rinsed three times with PBT, followed by a wash in 100 µl terminal deoxynucleotidyltransferase (TdT) equilibration buffer (from the Kit, DeadEnd Fluorometric TUNEL System Promega). For the enzymatic reaction, a working solution of TdT enzyme (30%) with the reaction buffer (70%) was made and added to the tissues. The samples were then incubated for 2 hr in a 37°C incubator and flickered every 30 min to mix the contents. The reaction was terminated by immersing the tissues in stop buffer (0.3 M NaCl/0.03 M sodium citrate) for 15 min at room temperature. DAPI (1:400) was used as a counterstain.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Cells undergo a constant shift between catabolism and anabolism to meet the metabolic needs of their growth. Biochemical and genetic studies using *Drosophila* provide critical insights into how cells achieve such a switch via the E3 ligase protein, TRIM32. In addition to its role in protein degradation, authors have shown that TRIM32 physically interacts with and stabilizes key glycolytic proteins, Aldolase and Phosphoglycerate mutase and controls glycolytic flux. Given that its function is proven in both the muscle and in overgrowing tissues, it will be interesting to see detailed molecular mechanisms of TRIM32 that may be conserved in other species.

**Decision letter after peer review:**

Thank you for submitting your article \"*Drosophila* TRIM32 cooperates with glycolytic enzymes to promote cell growth\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Utpal Banerjee as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see, all of the reviewers agreed on the significance of your work, but a number of critical criticisms were raised which require new experimental data and analyses. The full comments of the reviewers are attached to provide further details.

Summary:

In this study, authors have discovered a novel role for TRIM32 in the glycolytic control mediated by interactions with Aldolase and Pglym, enzymes responsible for the glycolytic pathway. Loss of TRIM32 leads to an overall loss of glycolytic flux and related metabolic parameters in the muscle. Furthermore, TRIM32 is required for the Pvr-induced tumor growth, demonstrating that TRIM32 is a critical regulator of glycolytic enzymes in both developing and cancer tissues. Overall, this study will be of interest to a broad audience studying metabolism, cancer, muscle biology, and the TRIM32 associated diseases, prompting future works.

Essential revisions:

1\) The authors need to demonstrate whether the *tn* mutant phenotype is cell-autonomous.

-- Tissue-specific knock-down or *tn*-/- mutant clones in the muscle/brain will address the concerns.

-- Quantifying food intake by *tn* mutant larvae will resolve a part of the issue.

2\) Related to concern \#1, there is only one *tn* mutant allele used in this study. It will be critical to show phenotypes of another *tn* mutant allele or multiple RNAi lines.

3\) Interactions between TRIM32 and Ald or Pglym were only shown in vitro. In vivo evidence of TRIM32-Ald or TRIM32-Pglym interaction will be needed.

4\) The metabolic phenotypes require further characterization including:

-- Respiration in *tn* mutants

-- Quantification/analysis or better explanations on glycolytic flux, glucose uptake and ATP production

-- Quantify glycolytic flux rates in the wing disc

-- Compare PER in *WT* and *tn* muscles

5\) Clarify the causality of the glycolytic defect and the muscle phenotypes.

The reviewers\' comments attached below are detailed and will help you improve the manuscript for publication.

Reviewer \#1:

In this study, Geisbrecht and authors have identified a novel role for TRIM32 in the control of glycolytic flux by physical interactions with Aldolase and Pglym. Authors have characterized structural homologies between the mammalian TRIM32 and *Drosophila* thin, and isolated glycolytic enzymes including Aldolase and Pglym as biochemical interactors. Loss of TRIM32 leads to an overall loss of glycolytic metabolites and 11 amino acids, and as a consequence, ATP levels significantly reduce in this background. Furthermore, authors have shown TRIM32 is required for the Pvr-induced tumor growth in the wing disc, concluding that TRIM32 is a critical regulator of glycolytic enzymes in both developing and cancerous tissues.

1\) Authors have indicated that *tn-/-* larvae significantly decreased ATP levels as well as glycolytic products. These metabolic consequences could be due to reduced food consumption or dysfunctions in the digestive system. Authors need to distinguish systemic developmental defects and cell-autonomous functions of *tn* mutants. It will be critical to include proper controls showing that the metabolic phenotype is not derived by *tn*-mediated systemic effects but by loss of *tn* in a specific tissue. As one of the examples, tissue-specific metabolic measurements after the loss of *tn* in the muscle or the brain could suitably support the query.

2\) The authors\' previous study on *tn* mutants has shown that loss of *tn* causes an overall reduction in the muscle and animal size. In Figure 4A, authors have claimed that *tn* mutants exhibit the significantly smaller size of the brain, in addition to the muscle. However, given that *tn* mutants are smaller in their size, it will be important to show proportional size changes of the brain and the muscle compared to the larval size changes.

3\) According to the Materials and methods, authors cultured *WT* or *tn* mutant larvae on the agar plate from very early stages and let them grow until the 3rd instar. However, *WT* animals marginally change their body mass and the muscle diameter after the chronic starvation (Figure 3F-I). How do larvae properly grow without any nutrition? Supporting references on the chronic starvation and normal growth, or some other control experiments would make the data more concrete and convincing.

4\) If NHL domain plays a unique role in protecting the glycolytic enzymes, a specific deletion or mutation on the NHL domain would provide more precise metabolic phenotypes while eliminating Ub-mediated complexities. It is not clear in the current version whether it is the NHL domain mutation that gives rise to the glycolytic phenotypes. It will be important to segregate non-canonical TRIM32 functions through NHL domain from Ub-mediated canonical phenotypes.

5\) In Figure 4E-H, authors have shown that the Pvr-induced tumor growth phenotype is recovered by loss of *tn*. Though the representative image in Figure 4F displays significantly bigger wing disc, the quantitation of the *dpp\>Pvr^act^* shown in Figure 4H indicates a comparable measurement to that of controls. Accurate measurement would enhance the clarity of data.

Reviewer \#2:

This is an interesting study uncovering a novel function for the disease-associated protein TRIM32. This will likely be of interest to a broad audience studying metabolism, muscle biology, as well as the TRIM32-associated diseases.

A number of issues need to be significantly strengthened, however, to make the main conclusions of this study solid:

1\) Does full-length TRIM32 bind Ald and Pglym in vivo? The authors only show an in vitro binding assay using recombinant proteins (likely in high molar concentrations) using a truncated TRIM32 version. Can these protein-protein interactions be observed by co-immunoprecipitation using full-length TRIM32 from tissue or cell lysates?

2\) It is not clear that the phenotypes described here are indeed cell-autonomous, as would be expected if they are due to glycolytic defects in the cells being studied. Since whole-body *tn* mutants are being studied, the phenotypes could be due to more complex organismal defects. Specifically, are the reduced size of muscle and brain cells cell-autonomous? If *tn* is knocked-down only in the brain or only in a small subset of larval muscles, or if *tn*- mutant clones are generated in the brain, does this result in small cell size?

3\) The metabolic phenotype is not sufficiently characterized:

-- Figure 2: A decrease in lactate production does not mean glycolytic flux is reduced -- it could also indicate an increase in respiration. The drop in steady-state pyruvate levels is not interpretable because it does not say anything about flux through pyruvate. (i.e. if twice as much pyruvate is made per unit of time, and twice as much pyruvate is used up, steady-state pyruvate levels will not change, showing that they do not say anything about flux). Is respiration increased in *tn* mutant cells?

-- It is highly unlikely, if indeed glycolytic flux is reduced, that there is no change in glucose uptake by these cells, as concluded in the manuscript, referring to Figure 4---figure supplement 2. Almost always, changes in glycolytic flux and glucose uptake correlate. Where would all the intracellular glucose go otherwise? Even if it shuttles into the PPP pathway it still returns to the glycolytic pathway as glyceraldehyde 3-phosphate and fructose 6-phosphate which requires Pglym to be metabolized... Hence Figure 4---figure supplement 2E-F would need to be quantified (e.g. cell dissociation and FACS? Or lysis and measuring fluorescence normalized to protein?) to conclude this more robustly.

-- The authors write \"The metabolism of growing cells must strike a balance between ATP production and the maintenance of metabolite pools that contribute to biomass production. The metabolomic profile of *tn*-/- larvae suggests that TRIM32 regulates this metabolic balance by promoting glycolytic flux, which results in the synthesis (and preservation) of amino acid pools for protein synthesis.\"

This conclusion does not appear to be correct. Indeed, more respiration will lead to more ATP synthesis and less biomass production. However, the *tn* mutants do not have less lactate and more ATP, but less of everything (less lactate, less ATP and less amino acids).

-- Is TRIM32 expressed in cells in culture (e.g. *Drosophila* S2 cells)? If so, these issues can be dissected much more easily in cell culture, but knocking down TRIM32 and quantitating glucose uptake, lactate production, and oxygen consumption. This would more rigorously show an effect on glycolytic flux.

4\) It is not clear that indeed a glycolytic defect is causing the muscle phenotypes.

The authors write \"To confirm that the smaller muscles in TRIM32-deficient larvae are indeed due to defective glycolysis, muscle carcasses were isolated and assessed for changes in metabolic activity\" -- this statement is misleading/incorrect. This approach only shows correlation, not causality.

-- There is no functional experiment in the manuscript showing that reduced glycolysis is causing the muscle phenotypes, or that restoring glycolytic flux rescues the phenotype.

5\) Importantly, from Figure 3F, the main conclusion that \"the addition of amino acid building blocks is sufficient to rescue a TRIM32-mediated loss of muscle mass.\" is not warranted.

The addition of yeast extract or amino acids does not \'rescue\' the muscle defect of *tn* mutants, i.e. it does not return the phenotype to wildtype levels. It simply rescues the additional defect caused by not feeding these animals any protein (agar only). This does not mean much. It is analogous to not feeding *tn* mutants any water and seeing that they dehydrate. Then giving them water again would return them to the original *tn* mutant phenotype, and thereby concluding that water is sufficient to rescue the TRIM32-mediated phenotype.

To prove that amino acid deficiency is causing the muscle atrophy phenotype, one would need to see that feeding additional amino acids (on top of the normal food) to *tn* mutants causes their muscle size to become more like wildtype.

6\) Could it be the other way around -- that a muscle defect is leading to an eating defect (which requires continuous muscle movement) and as a consequence, less intake of sugar and protein by the larvae, leading to the metabolic phenotypes? This can be resolved by:

-- quantifying food intake by *tn* mutant larvae;

--- checking the cell-autonomy of the metabolic defects;

-- testing in cell culture whether TRIM32 knockdown leads to the same glycolytic defects.

7\) Figure 4---figure supplement 1: it is difficult to judge whether apoptosis rates account for a difference in tissue size by just quantifying apoptosis, because this only yields a snapshot of apoptosis at that moment, whereas tissue size integrates apoptosis rates over time. So a change in apoptosis may appear mild at any one point, but result in significant tissue size differences over time. The way to prove this functionally is to block apoptosis, e.g. with p35. Alternatively, if the authors want to conclude that cell size in *tn* brains is smaller than in control brains, a direct quantification of cell size would be better.

8\) The authors write \"Wing discs are not inherently glycolytic and do not endogenously express LDH (Figure 4E). Accordingly, the overall area or volume of the disc was not affected by loss of TRIM32\"

This is not correct. Endogenous LDH (called ImpL3 in *Drosophila*) is expressed in wing discs, and can be detected by Q-RT-PCR or by in situ hybridization on endogenous transcript.

Hence, the fact that wing disc size is not decreased in TRIM32 mutants cannot be explained with this justification and raises the question whether indeed the metabolic mechanism the authors propose is correct.

9\) Along the same lines, there is no quantification of glycolytic flux rates in the wing discs -- neither that PVR expression causes them to increase, nor that the *tn* mutation causes them to drop again. The phenotype shown in Figure 4H simply says there is some genetic interaction, but this could be happening at any level.

In sum, between points \#4 and \#5, I do not see any solid evidence that a metabolic defect is causing the muscle phenotypes described here.

Reviewer \#3:

Bawa et al. describes compelling observations suggesting that TRIM32 is a key regulator of glycolysis in fast growing larval tissues. *Drosophila* TRIM32 ortholog Tn physically interacts with two enzymes, Aldolase and Pglym. Strikingly, loss of *tn* caused a reduction in Ald and Pglym protein levels, which might not be explained by its role as E3-ubiquitin ligase. Of importance, the authors present multiple pieces of data suggesting that Tn is required for maintaining the levels of metabolites produced by glycolysis and derived from glucose. Biochemical and physiological characterization of *tn* mutant shows that a main role of *tn* is to maintain amino acid pools to support growth presumably by maintaining glycolysis. Overall, the observations are quite interesting and novel, prompting follow-up studies to elucidate the molecular mechanisms by which Tn maintains glycolysis and address whether mammalian TRIM32 plays a similar role. The manuscript should be suitable for publication if the authors address the following comments.

1\) Proton efflux rate (PER), as shown with brain tissues in Figure 4D, provides a reasonable assessment of glycolytic flux in isolated tissues. In contrast, extracellular acidification rate (ECAR) is also influenced by CO~2~ produced during respiration; thus it wouldn\'t provide an accurate estimation of glycolytic flux. To clearly demonstrate *Drosophila* TRIM32 regulate glycolysis in larval muscle, it is critical to compare PER in wild-type and *tn* muscles.

2\) Only one *tn* mutant allele is used throughout the study. How can the authors rule out the possibility that the phenotypes observed with the *tn* allele is not due to a background mutation? One way to resolve this issue is to show that the key phenotypes, such as a reduction in PER, can be reversed by having a genomic rescue transgene or tissue specific rescue using GAL4/UAS system. Alternatively, it would be helpful to show that similar phenotypes can be seen with different *tn* alleles.

3\) Considering the hypothesis that TRIM32 is required for maintaining glycolytic flux, I would suggest to move the results in Figure 2---figure supplement 2C-D to the main figures. Note that the results shown in Figure 2C-G are not new; additionally, similar results are shown in Figure 3B-F. Thus, Figure 2C-G can be moved to the supplementary figures.

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"*Drosophila* TRIM32 cooperates with glycolytic enzymes to promote cell growth\" for further consideration by *eLife*. Your revised article has been evaluated by Utpal Banerjee as the Senior Editor, and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) As suggested by reviewer \#1 comment 2, reviewer \#2 comment 1-3, in vivo interactions between TRIM32 and Ald/Pglym are critical to prove the hypothesis, and therefore, require precise descriptions of experiments and results.

2\) Reviewer \#3 comment 2: ERR-mediated restoration experiments need better descriptions and if possible, additional data could be added.

3\) Other comments can be immediately addressed or edited.

Reviewer \#1:

Authors have significantly improved the manuscript and adequately addressed critiques raised by reviewers. There are some points below to be changed for better readability.

1\) In the line \"Importantly, protein levels of Ald....... ERR in *tn-/-* muscles, indicating that\~\", figure citation is missing. It could be Figure 2---figure supplement 2F-G.

2\) As suggested in the major revision 3, showing the in vivo interactions between TRIM32 and Ald/Pglym is essential for the study. Therefore, [Author response image 1](#respfig1){ref-type="fig"} needs to be moved to the main figure with additional explanations and discussions.

3\) Given that *tn* mutants exhibit reduced mouth hook contraction, the growth of *tn* mutants could be overall retarded while tissue-specific knockdown of *tn* showed no difference. Having the possibility of slow growth, showing the small-sized muscle or brain of *tn* mutants in main Figures 3-4 could be misleading. It will be more adequate to show the small size phenotypes with tissue-specific RNAi backgrounds.

Reviewer \#2:

The manuscript is significantly improved. For instance, the authors do a good job of showing the tissue-autonomous nature of the TRIM32 phenotypes.

Some issues which can be fixed without any additional experiments:

1\) The authors write in their rebuttal \"Identification of the TRIM32-Ald or TRIM32-Pglym biochemical interaction was performed in vivo using larval lysates (Figure 1C; Figure 1---figure supplement 2A...\". If I understand correctly, in Figure 1, a truncated version of TRIM32 was fused to GST, expressed recombinantly in bacteria, and purified. This was then incubated in a test tube with larval lysates. How can this be called \"in vivo\"? Some people call cells in culture \"in vivo\" and some people mean a live organism by \"in vivo\", but I do not think anyone considers a lysate in a test tube to be \"in vivo\"? If I misunderstood the experimental setup, it needs to be described better in the manuscript.

2\) Showing that full-length TRIM32 binds Ald and Pglym in vivo is critical for this story. I believe the results shown in [Author response image 1](#respfig1){ref-type="fig"} should be put into the manuscript.

3\) Regarding the fact that the co-IPed Ald and Pglym in [Author response image 1](#respfig1){ref-type="fig"} are running at a different molecular weight compared to Ald and Pglym in the input can either be interpreted as the authors write by post-translational modification of the pool of Ald and Pglym that interact with TRIM32, or it might simply be another contaminating protein that cross-reacts with the Ald and Pglym antibodies. Can this be distinguished? If it is a sub-population of the total Ald/Pglym, it should also be visible in the total lysates. Also, most post-translational modifications are readily lost in IP buffer and Laemmli (e.g. ubiquitination or phosphorylation), which would cause it to run at the \'normal\' size. This should be discussed.

4\) The authors write \"Surprisingly, cellular glucose uptake... was normal in *tn-/-* larval brains and wing discs... demonstrating that glucose is not a limiting substrate for glycolysis in these isolated tissues.\"

I believe this statement is not correct. How does this show glucose is not a limiting substrate for glycolysis in brains and wing discs? Or do the authors mean specifically in *tn* mutants?

Reviewer \#3:

The authors have appropriately addressed most of my comments. I have two additional comments:

1\) The authors showed that Ald and Pglym protein levels were reduced in *tn* mutant. However, the authors didn\'t show that TRIM32 stabilized these proteins. Thus, I suggest to revise the following sentences:

\"Here we provide a novel mechanism for TRIM32 in cell growth. Our data show that TRIM32 promotes glucose metabolism through the stabilization of glycolytic enzyme levels.\"

\"Taken together, these data highlight a unique role for TRIM32 in the stabilization of glycolytic enzyme levels.\"

\"Importantly, protein levels of Ald and Pglym were stabilized upon expression of ERR in *tn*-/- muscles, indicating that restoration of glycolytic protein levels is sufficient to recover TRIM32-mediated growth defects.\"

2\) Although the authors claimed that ERR overexpression stabilized Ald and Pglym levels, the results were not shown. Thus, the authors should test whether ERR overexpression could restore Ald and Pglym levels in *tn* mutant. Otherwise, the result regarding the ERR overexpression in muscle shown in Figure 2M is better to be removed. Additionally, given that ERR can impact on multiple targets, \"restoration of glycolytic protein levels is sufficient to recover TRIM32-mediated growth defects.\" is an overstatement.

10.7554/eLife.52358.sa2

Author response

> Essential revisions:
>
> 1\) The authors need to demonstrate whether the tn mutant phenotype is cell-autonomous.
>
> -- Tissue-specific knock-down or tn-/- mutant clones in the muscle/brain will address the concerns.

This is a great point. Multiple new experiments show that the *tn* mutant phenotype is cell-autonomous:

1\) Knockdown of TRIM32 using three independent RNAi lines all show a reduction in the diameter of L3 muscles upon induction with *mef2-*Gal4 (*tn RNAi-A, tn RNAi-B*, and *tn RNAi-C*) (Figure 2K; Figure 2---figure supplement 2A, B). Note that two of these RNA lines were previously published by us (LaBeau-DiMenna et al., 2012) and the Nguyen group (Domsch et al., 2013) to show the same small muscle phenotype as the *tn* alleles in this paper. We also show that knockdown of *tn RNAi-A* in a single muscle (*5053*-Gal4 driver) reduces cell size (Figure 2---figure supplement 2C).

2\) Brain-specific knockdown of TRIM32 using the pan-neuronal driver *elav*-Gal4 causes a smaller larval brain size, while knockdown of *tn RNAi* in muscles does not alter brain size (Figure 4C-G).

3\) Brain lactate levels are lower in *elav\>tn RNAi*, but not *mef2\>tn RNAi* brains (Figure 4I). The converse is also true, where muscle carcasses of the genotype *mef2\>tn RNAi* show a reduction in lactate levels, but not upon neuronal-specific depletion of TRIM32 (*elav\>tn RNAi*) (Figure 2L).

4\) While previously published (LaBeau-DiMenna et al., 2012; Domsch et al., 2013), we confirm that muscle-specific expression of *TRIM32 cDNA* rescues muscle cell size (Figure 2M), muscle function (Figure 2---figure supplement 2D, E), and stabilizes glycolytic enzyme levels (Figure 2---figure supplement 2F, G).

5\) Finally, two tissues that are not considered glycolytic in nature (wing disc and midgut), are not smaller in *tn* mutants. This is further evidence that TRIM32 affects glycolytic tissues (muscle and brain).

> -- Quantifying food intake by tn mutant larvae will resolve a part of the issue.

As suggested by multiple reviewers, muscle defects could lead to reduced feeding and thus produce whole body metabolic defects. To assay food intake, larvae were fed yeast mixed with a blue dye (Aditi et al., 2016). The amount of dye present in the gut of *WT, tn-/-,* or *tn RNAi* animals was quantified by measuring absorbance values at a wavelength of 600 nm. Not surprisingly, *tn-/-* larvae showed reduced mouth hook contractions and compromised ingestion of dye at both 3 and 24 hr (Figure 5---figure supplement 2E, I, J). However, larvae with reduced TRIM32 in larval muscle (*mef2\>tn RNAi*) or brain tissue (*elav\>tn RNAi*) showed no difference between control or RNAi knockdown conditions (Figure 5---figure supplement 2I, J). These data clearly demonstrate that a loss of TRIM32 in all tissues compromises food consumption, while the observed metabolic defects (e.g., lactate production) upon tissue-specific loss of TRIM32 are not nutrition limited.

> 2\) Related to concern \#1, there is only one tn mutant allele used in this study. It will be critical to show phenotypes of another tn mutant allele or multiple RNAi lines.

We should have emphasized this point in our initial submission. Our 2012 PNAS paper described three *tn* alleles \[*l(2)tn, tnΔA*, and *tnΔB*\] and one RNAi line (*tn RNAi-A*) that exhibit smaller, degenerative muscles (LaBeau-DiMenna et al., 2012). Soon after, the Nguyen lab published similar results using three additional alleles of *tn* as well as the *tn RNAi-A* and *tn RNAi-B* lines used in this paper (Domsch et al., 2013). Note that a later publication from our lab confirmed knockdown of *tn mRNA* transcripts for two *UAS-tn RNAi* lines by qPCR (Brooks et al., 2016). To further support our results, we now show in this manuscript that knockdown of three RNAi lines (*tn RNAi-A, tn RNAi-B,* and *tn RNAi-C*) in muscle tissue produce smaller muscles (Figure 2K) and also exhibit reduced lactate levels (Figure 2L).

> 3\) Interactions between TRIM32 and Ald or Pglym were only shown in vitro. In vivo evidence of TRIM32-Ald or TRIM32-Pglym interaction will be needed.

Identification of the TRIM32-Ald or TRIM32-Pglym biochemical interaction was performed in vivo using larval lysates (Figure 1C; Figure 1---figure supplement 2A) and we later developed the in vitro assay to validate these in vivo interactions (Figure 1D, E; Figure 1---figure supplement 2B). Nevertheless, to address reviewer concerns, we performed immunoprecipitations using anti-TRIM32 antibodies to pull down protein complexes from L3 larval lysates. As shown in [Author response image 1](#respfig1){ref-type="fig"}, we can pulldown TM, Ald, and Pglym and uncovered quite an interesting result. While the molecular weight of immunoprecipitated TM is as expected, we see higher molecular weight bands of Ald and Pglym in our anti-TRIM32 IPs that are suggestive of a post-translational modification (PTM). This verification of TRIM32-glycolytic enzyme complexes will be followed up to identify the nature of the PTM. We include a section at the end of the Discussion entitled 'Limitations of this study' that addresses how TRIM32 may function with glycolytic enzymes.

![Reviewer Figure 1.](elife-52358-resp-fig1){#respfig1}

> 4\) The metabolic phenotypes require further characterization including:
>
> -- Respiration in tn mutants

In Figure 2---figure supplement 1B, we show that CO~2~ production is mildly increased in *tn-/-* whole larvae. Given that multiple tissues with metabolic phenotypes may contribute to CO~2~ production, we further assessed PER in isolated muscle (Figure 2I) and brain (Figure 4H) tissue. These results confirm a tissue-specific decrease in glycolytic activity.

> -- Quantification/analysis or better explanations on glycolytic flux, glucose uptake and ATP production

As this is a short report, we limited text explanations in our original submission. In this revised version, the text has been extensively modified to improve readability. We have added multiple experiments (and associated analysis/explanations) to better assess glycolytic flux: (1) PER in isolated muscle carcasses (Figure 2I); (2) PER in wing discs (Figure 5---figure supplement 1D); (3) FLIM analysis in control and tumorous wing discs (Figure 5F, G).

> -- Quantify glycolytic flux rates in the wing disc

We now show that glycolytic flux rates, assessed by PER (Figure 5---figure supplement 1D) and FILM (Figure 5F, G), as well as overall wing disc size (Figure 5D, Figure 5---figure supplement 1C) are not different between *WT* and *tn-/-* wing discs. This negative result is very important as it demonstrates that the observed decreases in cell size due to loss of TRIM32 only affects highly glycolytic tissues for maximizing substrate production during rapid cell growth.

> -- Compare PER in WT and tn muscles

We now include PER data for *WT* and *tn-/-* muscles (Figure 2I). Our results show that glycolytic flux is reduced in TRIM32 mutant muscle tissue.

> 5\) Clarify the causality of the glycolytic defect and the muscle phenotypes.

To confirm that reduced glycolysis is indeed causing the reduction in muscle size, we expressed Estrogen-related receptor (ERR) in muscle tissue. ERR is a nuclear hormone receptor that acts as a transcriptional switch in embryogenesis to induce genes required for aerobic glycolysis during larval growth (Tennessen et al., 2011). Indeed, muscle-specific expression of ERR in *tn-/-* restores muscle size (Figure 2M), allows for muscle contraction (Figure 2---figure supplement 2D, E), and stabilizes the levels of Ald and Pglym (Figure 2---figure supplement 2F, G).

> The reviewers\' comments attached below are detailed and will help you improve the manuscript for publication.
>
> Reviewer \#1:
>
> \[...\]
>
> 1\) Authors have indicated that tn-/- larvae significantly decreased ATP levels as well as glycolytic products. These metabolic consequences could be due to reduced food consumption or dysfunctions in the digestive system. Authors need to distinguish systemic developmental defects and cell-autonomous functions of tn mutants. It will be critical to include proper controls showing that the metabolic phenotype is not derived by tn-mediated systemic effects but by loss of tn in a specific tissue. As one of the examples, tissue-specific metabolic measurements after the loss of tn in the muscle or the brain could suitably support the query.

Please see complete response above (Essential revisions \#1). In summary, we now show that muscle-specific or brain-specific loss of TRIM32 causes a reduction in L-lactate levels, independent of feed consumption.

> 2\) The authors\' previous study on tn mutants has shown that loss of tn causes an overall reduction in the muscle and animal size. In Figure 4A, authors have claimed that tn mutants exhibit the significantly smaller size of the brain, in addition to the muscle. However, given that tn mutants are smaller in their size, it will be important to show proportional size changes of the brain and the muscle compared to the larval size changes.

We previously showed that *tn* mutants cause a reduction in muscle cell size, but not overall animal size (a phenotype associated with growth defects) (LaBeau-DiMenna, et al. 2012). In fact, loss of TRIM32 results in elongated pupal cases due to defective muscle contraction during the larval to pupal transition (Figure 3H, I; Figure 2---figure supplement 2D, E). Thus, the smaller muscle and brain sizes affect only these tissues, but not the size of wing discs (Figure 5D; Figure 5---figure supplement 1A-C), midgut tissue (Figure 5---figure supplement 2F-H), or overall body size.

> 3\) According to the Materials and methods, authors cultured WT or tn mutant larvae on the agar plate from very early stages and let them grow until the 3rd instar. However, WT animals marginally change their body mass and the muscle diameter after the chronic starvation (Figure 3F-I). How do larvae properly grow without any nutrition? Supporting references on the chronic starvation and normal growth, or some other control experiments would make the data more concrete and convincing.

Thank you for bringing this to our attention as we should have explained this more clearly in our initial submission. The reviewer is correct that complete starvation during early larval development causes growth arrest and reduced size (Beadle et al., 1938; Robertson, 1966). Our larvae were reared on 2.25% agar, which contains an undefined amount of two polysaccharides, agarose and agaropectin. Thus, the larvae are not devoid of all nutrition. In our hands, *WT* larval growth is delayed with variable L3 body mass and muscle diameter (Figure 3F, G). Some *WT* larvae also die, but others are able to pupate, albeit reduced in size (Figure 3H, I). We have clarified this information in Materials and methods.

> 4\) If NHL domain plays a unique role in protecting the glycolytic enzymes, a specific deletion or mutation on the NHL domain would provide more precise metabolic phenotypes while eliminating Ub-mediated complexities. It is not clear in the current version whether it is the NHL domain mutation that gives rise to the glycolytic phenotypes. It will be important to segregate non-canonical TRIM32 functions through NHL domain from Ub-mediated canonical phenotypes.

Yes! We agree these are important experiments. Preliminary results in our lab show that deletion of the TRIM32 NHL domain fails to rescue *tn-/-* phenotypes in muscle (also published in Domsch et al., 2013). Experiments are underway to examine the necessity of human point mutations for maintaining glycolysis in muscles.

> 5\) In Figure 4E-H, authors have shown that the Pvr-induced tumor growth phenotype is recovered by loss of tn. Though the representative image in Figure 4F displays significantly bigger wing disc, the quantitation of the dpp\>Pvr^act^ shown in Figure 4H indicates a comparable measurement to that of controls. Accurate measurement would enhance the clarity of data.

There is indeed variability in wing disc area of *dpp\>Pvr^act^* tumors and measuring volume appears to better assess overall size (previously supplementary data). We now show volume measurements in Figure 5D and moved area data for wing discs to Figure 5---figure supplement 1C. Note there is a clear difference between tumors grown in *WT* or *tn-/-* backgrounds when area is measured.

> Reviewer \#2:
>
> This is an interesting study uncovering a novel function for the disease-associated protein TRIM32. This will likely be of interest to a broad audience studying metabolism, muscle biology, as well as the TRIM32-associated diseases.
>
> A number of issues need to be significantly strengthened, however, to make the main conclusions of this study solid:
>
> 1\) Does full-length TRIM32 bind Ald and Pglym in vivo? The authors only show an in vitro binding assay using recombinant proteins (likely in high molar concentrations) using a truncated TRIM32 version. Can these protein-protein interactions be observed by co-immunoprecipitation using full-length TRIM32 from tissue or cell lysates?

Please see our response above (Essential revisions \#3) and [Author response image 1](#respfig1){ref-type="fig"}.

> 2\) It is not clear that the phenotypes described here are indeed cell-autonomous, as would be expected if they are due to glycolytic defects in the cells being studied. Since whole-body tn mutants are being studied, the phenotypes could be due to more complex organismal defects. Specifically, are the reduced size of muscle and brain cells cell-autonomous ? If tn is knocked-down only in the brain or only in a small subset of larval muscles, or if tn- mutant clones are generated in the brain, does this result in small cell size?

This data is now included (Figure 2M; Figure 2---figure supplement 2A-C; Figure 2L; Figure 4C-G; Figure 4I). Please see previous responses (Essential revisions \#1 and reviewer \#1, point \#1).

> 3\) The metabolic phenotype is not sufficiently characterized:
>
> -- Figure 2: A decrease in lactate production does not mean glycolytic flux is reduced -- it could also indicate an increase in respiration. The drop in steady-state pyruvate levels is not interpretable because it does not say anything about flux through pyruvate. (i.e. if twice as much pyruvate is made per unit of time, and twice as much pyruvate is used up, steady-state pyruvate levels will not change, showing that they do not say anything about flux). Is respiration increased in tn mutant cells?

This is a great point. This data is now included (Figure 2---figure supplement 2B). Please see responses above (Essential revisions \#4) and the revised text.

> -- It is highly unlikely, if indeed glycolytic flux is reduced, that there is no change in glucose uptake by these cells, as concluded in the manuscript, referring to Figure 4---figure supplement 2. Almost always, changes in glycolytic flux and glucose uptake correlate. Where would all the intracellular glucose go otherwise? Even if it shuttles into the PPP pathway it still returns to the glycolytic pathway as glyceraldehyde 3-phosphate and fructose 6-phosphate which requires Pglym to be metabolized... Hence Figure 4---figure supplement 2E-F would need to be quantified (e.g. cell dissociation and FACS? Or lysis and measuring fluorescence normalized to protein?) to conclude this more robustly.

This result is surprising to us as well. Since we did not look at glucose uptake in other tissues or quantify differences using cell dissociation and FACS, it is possible there are minor changes that we were not able to observe. Nevertheless, we can conclude that the tissue-specific reductions in cell size are independent of nutrient status (Figure 5---figure supplement A-J).

> -- The authors write \"The metabolism of growing cells must strike a balance between ATP production and the maintenance of metabolite pools that contribute to biomass production. The metabolomic profile of tn-/- larvae suggests that TRIM32 regulates this metabolic balance by promoting glycolytic flux, which results in the synthesis (and preservation) of amino acid pools for protein synthesis.\"
>
> This conclusion does not appear to be correct. Indeed, more respiration will lead to more ATP synthesis and less biomass production. However, the tn mutants do not have less lactate and more ATP, but less of everything (less lactate, less ATP and less amino acids).

We have removed these sentences entirely.

> -- Is TRIM32 expressed in cells in culture (e.g. Drosophila S2 cells)? If so, these issues can be dissected much more easily in cell culture, but knocking down TRIM32 and quantitating glucose uptake, lactate production, and oxygen consumption. This would more rigorously show an effect on glycolytic flux.

We agree that cell culture can sometimes be an easier system to dissect cellular mechanisms, but we feel it is not ideal for our current studies. *Drosophila* S2 cells are not inherently glycolytic, although stress conditions can induce a shift in glucose metabolism from oxidative phosphorylation to glycolysis (Freije et al., 2012; Lee et al., 2015).

> 4\) It is not clear that indeed a glycolytic defect is causing the muscle phenotypes.
>
> The authors write \"To confirm that the smaller muscles in TRIM32-deficient larvae are indeed due to defective glycolysis, muscle carcasses were isolated and assessed for changes in metabolic activity\" -- this statement is misleading/incorrect. This approach only shows correlation, not causality.

This statement has been deleted due to massive text revisions. See also previous responses (Essential revisions \#1, \#3, \#5) as we now prove that a decrease in glycolytic activity causes smaller muscle size.

> -- There is no functional experiment in the manuscript showing that reduced glycolysis is causing the muscle phenotypes, or that restoring glycolytic flux rescues the phenotype.

This is a great suggestion. As we detailed above (Essential revisions \#5), we now show that induction of carbohydrate metabolism genes by ERR restores glycolytic protein levels and muscle mass. These results provide strong evidence for a causal link between glycolysis and the accumulation of biomass in muscle tissue.

> 5\) Importantly, from Figure 3F, the main conclusion that \"the addition of amino acid building blocks is sufficient to rescue a TRIM32-mediated loss of muscle mass.\" is not warranted.
>
> The addition of yeast extract or amino acids does not \'rescue\' the muscle defect of tn mutants, i.e. it does not return the phenotype to wildtype levels. It simply rescues the additional defect caused by not feeding these animals any protein (agar only). This does not mean much. It is analogous to not feeding tn mutants any water and seeing that they dehydrate. Then giving them water again would return them to the original tn mutant phenotype, and thereby concluding that water is sufficient to rescue the TRIM32-mediated phenotype.
>
> To prove that amino acid deficiency is causing the muscle atrophy phenotype, one would need to see that feeding additional amino acids (on top of the normal food) to tn mutants causes their muscle size to become more like wildtype.

This entire section has been rewritten.

> 6\) Could it be the other way around -- that a muscle defect is leading to an eating defect (which requires continuous muscle movement) and as a consequence, less intake of sugar and protein by the larvae, leading to the metabolic phenotypes? This can be resolved by:
>
> -- quantifying food intake by tn mutant larvae;
>
> -- checking the cell-autonomy of the metabolic defects;
>
> -- testing in cell culture whether TRIM32 knockdown leads to the same glycolytic defects.

This is a really great point and has now been addressed. Please see previous responses (Essential revisions \#1; reviewer \#1, point \#1; reviewer \#2, point \#3)

> 7\) Figure 4---figure supplement 1: it is difficult to judge whether apoptosis rates account for a difference in tissue size by just quantifying apoptosis, because this only yields a snapshot of apoptosis at that moment, whereas tissue size integrates apoptosis rates over time. So a change in apoptosis may appear mild at any one point, but result in significant tissue size differences over time. The way to prove this functionally is to block apoptosis, e.g. with p35. Alternatively, if the authors want to conclude that cell size in tn brains is smaller than in control brains, a direct quantification of cell size would be better.

We have now measured the area of cells in the lobes of the developing larval brain. Although quite variable in size depending on their cell lineage and/or the timing of cell division, there is a clear overall reduction in cell area upon loss of TRIM32 (Figure 4---figure supplement 1J-M).

> 8\) The authors write \"Wing discs are not inherently glycolytic and do not endogenously express LDH (Figure 4E). Accordingly, the overall area or volume of the disc was not affected by loss of TRIM32\"
>
> This is not correct. Endogenous LDH (called ImpL3 in Drosophila) is expressed in wing discs, and can be detected by Q-RT-PCR or by in situ hybridization on endogenous transcript.
>
> Hence, the fact that wing disc size is not decreased in TRIM32 mutants cannot be explained with this justification and raises the question whether indeed the metabolic mechanism the authors propose is correct.

Thank you for pointing this out. We simply meant that wing discs are not considered a tissue with enhanced glycolytic activity and that LDH-GFP is not enriched in *WT* wing discs \[consistent with published data that endogenous LDH activity is not readily detectable in wing and eye discs (Wang et al., 2016)\]. We have corrected this statement to read, 'Unlike muscle or brain tissue, neither LDH activity (Wang et al., 2016) nor LDH-GFP expression (Figure 5A) were detectable in control wing discs, suggesting that this tissue does not exhibit elevated glycolytic activity.'

> 9\) Along the same lines, there is no quantification of glycolytic flux rates in the wing discs -- neither that PVR expression causes them to increase, nor that the tn mutation causes them to drop again. The phenotype shown in Figure 4H simply says there is some genetic interaction, but this could be happening at any level.
>
> We now include FILM data (Figure 5G) that demonstrate differences in the glycolytic profile between PVR tumors grown in *WT* or *tn-/-* larvae. Although variable among individual discs, there is a trend of elevated glycolytic flux in PVR-induced tumors that is significantly reduced when these tumors are grown in *tn-/-* larvae. Note that PER analysis is not possible with *tn-/-; dpp\>Pvr^act^* discs since the isolated tumors are small and does not give enough protein for normalization. It was not trivial to isolate *WT* or *tn-/-* wing discs with proper normalization due to small size of the tissue (Figure 5---figure supplement 2D).
>
> Reviewer \#3:
>
> \[...\]
>
> 1\) Proton efflux rate (PER), as shown with brain tissues in Figure 4D, provides a reasonable assessment of glycolytic flux in isolated tissues. In contrast, extracellular acidification rate (ECAR) is also influenced by CO~2~ produced during respiration; thus it wouldn\'t provide an accurate estimation of glycolytic flux. To clearly demonstrate Drosophila TRIM32 regulate glycolysis in larval muscle, it is critical to compare PER in wild-type and tn muscles.

We agree that this experiment is critical. We now include PER data for dissected *WT* and *tn-/-* muscle tissue (Figure 2I). Since the PER assay reports acidification of the media due to glycolysis and not resulting from TCA cycle metabolism, our results clearly show that loss of TRIM32 reduces glycolytic flux in muscle tissue.

> 2\) Only one tn mutant allele is used throughout the study. How can the authors rule out the possibility that the phenotypes observed with the tn allele is not due to a background mutation? One way to resolve this issue is to show that the key phenotypes, such as a reduction in PER, can be reversed by having a genomic rescue transgene or tissue specific rescue using GAL4/UAS system. Alternatively, it would be helpful to show that similar phenotypes can be seen with different tn alleles.

We now have this data. Please see previous responses (Essential revisions \#2; reviewer \#1, point \#2).

> 3\) Considering the hypothesis that TRIM32 is required for maintaining glycolytic flux, I would suggest to move the results in Figure 2---figure supplement 2C-D to the main figures. Note that the results shown in Figure 2C-G are not new; additionally, similar results are shown in Figure 3B-F. Thus, Figure 2C-G can be moved to the supplementary figures.

We appreciate this suggestion. In our revised version, we moved Western blots that show TRIM32 regulates Ald and Pglym protein levels to Figure 1E and G. We chose not to move the muscle pictures in Figure 2C-G to supplementary data as we want to clearly establish the decrease in muscle cell size during larval development (L2 to L3 stages).

\[Editors\' note: further revisions were suggested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) As suggested by reviewer \#1 comment 2, reviewer \#2 comment 1-3, in vivo interactions between TRIM32 and Ald/Pglym are critical to prove the hypothesis, and therefore, require precise descriptions of experiments and results.

We have now included this data in a new Figure 2 and Figure 2---figure supplement 1. We observe a higher molecular weight form of Ald and Pglym upon immunoprecipitation of TRIM32 from L3 larval lysates. Note that we can visualize the modified forms of these proteins using antibodies generated against *Drosophila* Ald or Pglym (Figure 2C,D) as well as antibodies against human ALD or PGAM1 that cross-react with the fly protein (Figure 2---figure supplement 1D, E). Experimental descriptions, methods, and results are included in the modified manuscript. Please also see explanations in response to reviewers \#1 and \#2 below.

> 2\) Reviewer \#3 comment 2: ERR-mediated restoration experiments need better descriptions and if possible, additional data could be added.

Data showing that ERR expression restores glycolytic protein levels was included in our previous revision in a supplementary figure. This data has now been moved to a new Figure 4 where we show that ERR, which transcriptionally induces glycolytic gene expression, also restores muscle mass and muscle contraction upon loss of TRIM32. Please see detailed explanations in response to reviewer \#3 below.

> 3\) Other comments can be immediately addressed or edited.

Other comments have been addressed in the manuscript and are detailed below.

> Reviewer \#1:
>
> Authors have significantly improved the manuscript and adequately addressed critiques raised by reviewers. There are some points below to be changed for better readability.
>
> 1\) In the line \"Importantly, protein levels of Ald.... ERR in tn-/- muscles, indicating that\~\", figure citation is missing. It could be Figure 2---figure supplement 2F-G.

Thank you for catching this. Our failure to add this citation explains why reviewer \#3 did not notice this data (\#2 above in Essential revisions). This data has now been moved to a new Figure 4I and J.

> 2\) As suggested in the major revision 3, showing the in vivo interactions between TRIM32 and Ald/Pglym is essential for the study. Therefore, [Author response image 1](#respfig1){ref-type="fig"} needs to be moved to the main figure with additional explanations and discussions.

As discussed above in Essential revision \#1, we have now included this data a new Figure 2 and Figure 2---figure supplement 1.

> 3\) Given that tn mutants exhibit reduced mouth hook contraction, the growth of tn mutants could be overall retarded while tissue-specific knockdown of tn showed no difference. Having the possibility of slow growth, showing the small-sized muscle or brain of tn mutants in main Figures 3-4 could be misleading. It will be more adequate to show the small size phenotypes with tissue-specific RNAi backgrounds.

We have now moved tissue-specific data that was previously in supplementary data to main Figure 4. Specifically, knockdown of TRIM32 in muscle reduces muscle size (Figure 4A-D), but does not alter growth of the larval brain (Figure 6E-G).

> Reviewer \#2:
>
> The manuscript is significantly improved. For instance, the authors do a good job of showing the tissue-autonomous nature of the TRIM32 phenotypes.
>
> Some issues which can be fixed without any additional experiments:
>
> 1\) The authors write in their rebuttal \"Identification of the TRIM32-Ald or TRIM32-Pglym biochemical interaction was performed in vivo using larval lysates (Figure 1C; Figure 1---figure supplement 2A...\". If I understand correctly, in Figure 1, a truncated version of TRIM32 was fused to GST, expressed recombinantly in bacteria, and purified. This was then incubated in a test tube with larval lysates. How can this be called \"in vivo\"? Some people call cells in culture \"in vivo\" and some people mean a live organism by \"in vivo\", but I do not think anyone considers a lysate in a test tube to be \"in vivo\"? If I misunderstood the experimental setup, it needs to be described better in the manuscript.

The reviewer is correct and we now include in vivo data showing that immunoprecipitation of TRIM32 co-purifies with Ald and Pglym (new Figure 2C, D).

> 2\) Showing that full-length TRIM32 binds Ald and Pglym in vivo is critical for this story. I believe the results shown in [Author response image 1](#respfig1){ref-type="fig"} should be put into the manuscript.

As stated above, we moved this data to Figure 2.

> 3\) Regarding the fact that the co-IPed Ald and Pglym in [Author response image 1](#respfig1){ref-type="fig"} are running at a different molecular weight compared to Ald and Pglym in the input can either be interpreted as the authors write by post-translational modification of the pool of Ald and Pglym that interact with TRIM32, or it might simply be another contaminating protein that cross-reacts with the Ald and Pglym antibodies. Can this be distinguished? If it is a sub-population of the total Ald/Pglym, it should also be visible in the total lysates. Also, most post-translational modifications are readily lost in IP buffer and Laemmli (e.g. ubiquitination or phosphorylation), which would cause it to run at the \'normal\' size. This should be discussed.

Great point. We have verified the higher molecular weight bands corresponding to Ald or Pglym using additional antibodies raised against human ALD or PGAM1. Due to the high conservation of glycolytic enzymes, these antibodies cross-react with fly proteins. Note that IPs were carried out with guinea pig antibodies and Western blots were performed with antibodies raised in rabbit, ruling out heavy or light chain reactivity. We also can see a small proportion of this modified band when we overexpose concentrated lysates and have included discussion of these results.

> 4\) The authors write \"Surprisingly, cellular glucose uptake... was normal in tn-/- larval brains and wing discs... demonstrating that glucose is not a limiting substrate for glycolysis in these isolated tissues.\"
>
> I believe this statement is not correct. How does this show glucose is not a limiting substrate for glycolysis in brains and wing discs? Or do the authors mean specifically in tn mutants?

Yes, we meant specifically in *tn* mutants. This has been corrected.

> Reviewer \#3:
>
> The authors have appropriately addressed most of my comments. I have two additional comments:
>
> 1\) The authors showed that Ald and Pglym protein levels were reduced in tn mutant. However, the authors didn\'t show that TRIM32 stabilized these proteins. Thus, I suggest to revise the following sentences:

This data was present in our submitted revision (Figure 2---figure supplement 2F-G). To make this point more clearly, we have now moved this data to a new Figure 4I, J. Hence, we have chosen to keep the following sentences as written.

> \"Here we provide a novel mechanism for TRIM32 in cell growth. Our data show that TRIM32 promotes glucose metabolism through the stabilization of glycolytic enzyme levels.\"
>
> \"Taken together, these data highlight a unique role for TRIM32 in the stabilization of glycolytic enzyme levels.\"
>
> \"Importantly, protein levels of Ald and Pglym were stabilized upon expression of ERR in tn-/- muscles, indicating that restoration of glycolytic protein levels is sufficient to recover TRIM32-mediated growth defects.\"
>
> 2\) Although the authors claimed that ERR overexpression stabilized Ald and Pglym levels, the results were not shown. Thus, the authors should test whether ERR overexpression could restore Ald and Pglym levels in tn mutant. Otherwise, the result regarding the ERR overexpression in muscle shown in Figure 2M is better to be removed. Additionally, given that ERR can impact on multiple targets, \"restoration of glycolytic protein levels is sufficient to recover TRIM32-mediated growth defects.\" is an overstatement.

As mentioned previously, this data was present in our submitted revision (Figure 2---figure supplement 2F-G). To make it more visible, we have now moved this data to a new Figure 4I, J. Not only do we show that ERR can stabilize protein levels in *tn-/-,* but it can also restore muscle size and muscle contraction.
